Medtronic plc - Quarter Report: 2020 January (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q


☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended	January 24, 2020

☐	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________

Commission File Number 001-36820


MEDTRONIC PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)

Ireland			98-1183488
(State of incorporation)			(I.R.S. Employer Identification No.)

20 On Hatch, Lower Hatch Street

Dublin 2, Ireland

(Address of principal executive offices) (Zip Code)

+353 1 438-1700

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Ordinary shares, par value $0.0001 per share	MDT	New York Stock Exchange
Floating Rate Notes due 2021	MDT/21	New York Stock Exchange
0.000% Senior Notes due 2021	MDT/21A	New York Stock Exchange
0.000% Senior Notes due 2022	MDT/22B	New York Stock Exchange
0.375% Senior Notes due 2023	MDT/23B	New York Stock Exchange
0.25% Senior Notes due 2025	MDT/25	New York Stock Exchange
1.125% Notes due 2027	MDT/27	New York Stock Exchange
1.625% Notes due 2031	MDT/31	New York Stock Exchange
1.00% Senior Notes due 2031	MDT/31A	New York Stock Exchange
2.250% Notes due 2039	MDT/39A	New York Stock Exchange
1.50% Senior Notes due 2039	MDT/39B	New York Stock Exchange
1.75% Senior Notes due 2049	MDT/49	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Emerging growth company

☐

Non-accelerated filer

☐

Smaller Reporting Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 1(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of February 25, 2020, 1,340,166,137 ordinary shares, par value $0.0001, and 1,872 A preferred shares, par value $1.00, of the registrant were outstanding.

TABLE OF CONTENTS


Item	Description	Page

	PART I
1.	Financial Statements (unaudited)	1
2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	54
3.	Quantitative and Qualitative Disclosures About Market Risk	75
4.	Controls and Procedures	76
	PART II
1.	Legal Proceedings	76

2.	Unregistered Sales of Equity Securities and Use of Proceeds	76
6.	Exhibits	77
	Signatures	78

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

Medtronic plc

Consolidated Statements of Income

(Unaudited)


	Three months ended						Nine months ended
(in millions, except per share data)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Net sales	$	7,717	$	7,546	$	22,916	$	22,411
Costs and expenses:
Cost of products sold	2,400		2,265		7,160		6,672
Research and development expense	573		561		1,763		1,736
Selling, general, and administrative expense	2,587		2,596		7,750		7,798
Amortization of intangible assets	436		436		1,317		1,327
Restructuring charges, net	13		26		87		112
Certain litigation charges	108		63		276		166

Other operating (income) expense, net	(39)		57		88		278
Operating profit	1,639		1,542		4,475		4,322
Other non-operating income, net	(96)		(71)		(305)		(309)
Interest expense	156		243		930		726
Income before income taxes	1,579		1,370		3,850		3,905
Income tax provision	(340)		99		(317)		437
Net income	1,919		1,271		4,167		3,468
Net income attributable to noncontrolling interests	(4)		(2)		(24)		(9)
Net income attributable to Medtronic	$	1,915	$	1,269	$	4,143	$	3,459
Basic earnings per share	$	1.43	$	0.95	$	3.09	$	2.57
Diluted earnings per share	$	1.42	$	0.94	$	3.07	$	2.54
Basic weighted average shares outstanding	1,340.5		1,342.8		1,340.7		1,348.1
Diluted weighted average shares outstanding	1,351.5		1,352.7		1,351.6		1,359.5

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Consolidated Statements of Comprehensive Income

(Unaudited)


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Net income	$	1,919	$	1,271	$	4,167	$	3,468

Other comprehensive income (loss), net of tax:
Unrealized gain on investment securities	20		32		93		23
Translation adjustment	32		128		(116)		(1,127)
Net investment hedge	35		—		187		—
Net change in retirement obligations	13		17		38		65
Unrealized (loss) gain on cash flow hedges	(35)		(23)		(37)		317
Other comprehensive income (loss)	65		154		165		(722)
Comprehensive income including noncontrolling interests	1,984		1,425		4,332		2,746
Comprehensive income attributable to noncontrolling interests	(4)		(2)		(24)		(6)
Comprehensive income attributable to Medtronic	$	1,980	$	1,423	$	4,308	$	2,740

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Consolidated Balance Sheets

(Unaudited)


(in millions)	January 24, 2020		April 26, 2019
ASSETS

Current assets:
Cash and cash equivalents	$	3,709	$	4,393
Investments	7,919		5,455
Accounts receivable, less allowances of $205 and $190, respectively	6,248		6,222
Inventories, net	4,122		3,753
Other current assets	2,045		2,144
Total current assets	24,043		21,967

Property, plant, and equipment	11,507		10,920
Accumulated depreciation	(6,743)		(6,245)
Property, plant, and equipment, net	4,764		4,675
Goodwill	40,091		39,959
Other intangible assets, net	19,456		20,560
Tax assets	2,272		1,519
Other assets	2,196		1,014
Total assets	$	92,822	$	89,694

LIABILITIES AND EQUITY

Current liabilities:
Current debt obligations	$	844	$	838
Accounts payable	1,945		1,953
Accrued compensation	1,909		2,189
Accrued income taxes	457		567
Other accrued expenses	3,580		2,925
Total current liabilities	8,735		8,472

Long-term debt	24,732		24,486
Accrued compensation and retirement benefits	1,598		1,651
Accrued income taxes	2,738		2,838
Deferred tax liabilities	1,282		1,278
Other liabilities	1,784		757
Total liabilities	40,869		39,482

Commitments and contingencies (Note 17)

Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,340,786,042 and 1,340,697,595 shares issued and outstanding, respectively	—		—
Additional paid-in capital	26,144		26,532
Retained earnings	28,210		26,270
Accumulated other comprehensive loss	(2,546)		(2,711)
Total shareholders’ equity	51,808		50,091
Noncontrolling interests	145		121
Total equity	51,953		50,212
Total liabilities and equity	$	92,822	$	89,694

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Consolidated Statements of Equity

(Unaudited)


	Ordinary Shares					Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Total Shareholders’ Equity		Noncontrolling Interests		Total Equity
(in millions)	Number	Par Value
April 26, 2019	1,341	$	—	$	26,532	$	26,270	$	(2,711)	$	50,091	$	121	$	50,212
Net income	—	—		—		864		—		864		13		877
Other comprehensive income	—	—		—		—		227		227		—		227
Dividends to shareholders ($0.54 per ordinary share)	—	—		—		(724)		—		(724)		—		(724)
Issuance of shares under stock purchase and award plans	3	—		205		—		—		205		—		205
Repurchase of ordinary shares	(3)	—		(328)		—		—		(328)		—		(328)
Stock-based compensation	—	—		61		—		—		61		—		61
Cumulative effect of change in accounting principle⁽¹⁾	—	—		—		(33)		—		(33)		—		(33)
July 26, 2019	1,341	$	—	$	26,470	$	26,377	$	(2,484)	$	50,363	$	134	$	50,497
Net income	—	—		—		1,364		—		1,364		7		1,371
Other comprehensive (loss)	—	—		—		—		(127)		(127)		—		(127)
Dividends to shareholders ($0.54 per ordinary share)	—	—		—		(723)		—		(723)		—		(723)
Issuance of shares under stock purchase and award plans	4	—		145		—		—		145		—		145
Repurchase of ordinary shares	(5)	—		(552)		—		—		(552)		—		(552)
Stock-based compensation	—	—		108		—		—		108		—		108


October 25, 2019	1,340	$	—	$	26,171	$	27,018	$	(2,611)	$	50,578	$	141	$	50,719
Net income	—	—		—		1,915		—		1,915		4		1,919
Other comprehensive income	—	—		—		—		65		65		—		65
Dividends to shareholders ($0.54 per ordinary share)	—	—		—		(723)		—		(723)		—		(723)
Issuance of shares under stock purchase and award plans	3	—		143		—		—		143		—		143
Repurchase of ordinary shares	(2)	—		(236)		—		—		(236)		—		(236)
Stock-based compensation	—	—		66		—		—		66		—		66


January 24, 2020	1,341	$	—	$	26,144	$	28,210	$	(2,546)	$	51,808	$	145	$	51,953

(1) See Note 2 to the consolidated financial statements for discussion regarding the adoption of accounting standards during the first quarter of fiscal year 2020. 

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Consolidated Statements of Equity

(Unaudited)


	Ordinary Shares					Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Total Shareholders’ Equity		Noncontrolling Interests		Total Equity
(in millions)	Number	Par Value
April 27, 2018	1,354	$	—	$	28,127	$	24,379	$	(1,786)	$	50,720	$	102	$	50,822
Net income	—	—		—		1,075		—		1,075		2		1,077
Other comprehensive (loss)	—	—		—		—		(584)		(584)		—		(584)
Dividends to shareholders ($0.50 per ordinary share)	—	—		—		(677)		—		(677)		—		(677)
Issuance of shares under stock purchase and award plans	7	—		446		—		—		446		—		446
Repurchase of ordinary shares	(9)	—		(820)		—		—		(820)		—		(820)
Stock-based compensation	—	—		64		—		—		64		—		64
Changes to noncontrolling ownership interests	—	—		—		—		—		—		1		1
Cumulative effect of change in accounting principle⁽¹⁾	—	—		—		(47)		47		—		—		—
July 27, 2018	1,352	$	—	$	27,817	$	24,730	$	(2,323)	$	50,224	$	105	$	50,329
Net income	—	—		—		1,115		—		1,115		5		1,120
Other comprehensive (loss)	—	—		—		—		(289)		(289)		(3)		(292)
Dividends to shareholders ($0.50 per ordinary share)	—	—		—		(674)		—		(674)		—		(674)
Issuance of shares under stock purchase and award plans	7	—		298		—		—		298		—		298
Repurchase of ordinary shares	(13)	—		(1,171)		—		—		(1,171)		—		(1,171)
Stock-based compensation	—	—		104		—		—		104		—		104


October 26, 2018	1,346	$	—	$	27,048	$	25,171	$	(2,612)	$	49,607	$	107	$	49,714
Net income	—	—		—		1,269		—		1,269		2		1,271
Other comprehensive income	—	—		—		—		154		154		—		154
Dividends to shareholders ($0.50 per ordinary share)	—	—		—		(671)		—		(671)		—		(671)
Issuance of shares under stock purchase and award plans	2	—		82		—		—		82		—		82
Repurchase of ordinary shares	(7)	—		(672)		—		—		(672)		—		(672)
Stock-based compensation	—	—		60		—		—		60		—		60
Changes to noncontrolling ownership interests	—	—		—		—		—		—		3		3

January 25, 2019	1,341	$	—	$	26,518	$	25,769	$	(2,458)	$	49,829	$	112	$	49,941

(1) The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018.

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Consolidated Statements of Cash Flows

(Unaudited)


	Nine months ended
(in millions)	January 24, 2020		January 25, 2019
Operating Activities:
Net income	$	4,167	$	3,468
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,991		1,992


Provision for doubtful accounts	67		55
Deferred income taxes	(793)		(205)
Stock-based compensation	235		228
Loss on debt extinguishment	406		—


Other, net	140		111
Change in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net	(119)		(140)
Inventories, net	(346)		(367)
Accounts payable and accrued liabilities	103		211
Other operating assets and liabilities	(67)		(433)


Net cash provided by operating activities	5,784		4,920
Investing Activities:
Acquisitions, net of cash acquired	(199)		(1,615)

Additions to property, plant, and equipment	(877)		(799)
Purchases of investments	(8,249)		(1,987)
Sales and maturities of investments	5,791		4,159
Other investing activities	(34)		(3)
Net cash used in investing activities	(3,568)		(245)
Financing Activities:

Change in current debt obligations, net	17		(696)


Issuance of long-term debt	5,568		3
Payments on long-term debt	(5,606)		(29)
Dividends to shareholders	(2,170)		(2,022)
Issuance of ordinary shares	585		891
Repurchase of ordinary shares	(1,208)		(2,728)
Other financing activities	(74)		10
Net cash used in financing activities	(2,888)		(4,571)
Effect of exchange rate changes on cash and cash equivalents	(12)		(70)
Net change in cash and cash equivalents	(684)		34
Cash and cash equivalents at beginning of period	4,393		3,669
Cash and cash equivalents at end of period	$	3,709	$	3,703

Supplemental Cash Flow Information
Cash paid for:
Income taxes	$	639	$	1,206
Interest	348		540

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

1. Basis of Presentation

The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.

The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019. The Company’s fiscal years 2020, 2019, and 2018 will end or ended on April 24, 2020, April 26, 2019, and April 27, 2018, respectively. The Company's fiscal year 2021 is a 53-week year, with the extra week occurring during the first quarter, and will end on April 30, 2021.

2. New Accounting Pronouncements

Recently Adopted

Leases

In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020.

During the implementation of this recently adopted accounting standard, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component.

The adoption of this guidance resulted in the recognition of right-of-use assets and lease liabilities in an amount of approximately $1.0 billion, an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures. The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows.

Others

In August 2017, the FASB issued guidance to better align an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The Company adopted this guidance in the first quarter of fiscal year 2020. The adoption of this guidance resulted in expanded disclosures and did not have an impact on the Company's consolidated financial statements.

Not Yet Adopted

In June 2016, the FASB issued guidance which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The new standard will be effective for the Company in the first quarter of fiscal year 2021. The Company does not expect the adoption of the guidance to have a material impact on the Company’s consolidated financial statements.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

3. Revenue

The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, renal disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations.

The table below illustrates net sales by segment and division for the three and nine months ended January 24, 2020 and January 25, 2019:


	Three months ended⁽¹⁾						Nine months ended⁽¹⁾
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cardiac Rhythm & Heart Failure	$	1,393	$	1,397	$	4,201	$	4,295
Coronary & Structural Heart	948		913		2,844		2,736
Aortic, Peripheral, & Venous	478		476		1,420		1,424
Cardiac and Vascular Group	2,819		2,786		8,464		8,455
Surgical Innovations	1,474		1,434		4,345		4,224
Respiratory, Gastrointestinal, & Renal	702		690		2,073		1,999
Minimally Invasive Therapies Group	2,176		2,124		6,418		6,223
Brain Therapies	795		732		2,307		2,107
Spine	674		655		2,023		1,963
Specialty Therapies	340		325		996		956
Pain Therapies	303		314		910		942
Restorative Therapies Group	2,111		2,026		6,235		5,968
Diabetes Group	610		610		1,798		1,765
Total	$	7,717	$	7,546	$	22,916	$	22,411

(1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

During the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines previously included in Specialty Therapies to a product line under Brain Therapies. As a result, net sales for fiscal year 2019 have been recast to adjust for this realignment.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The table below illustrates net sales by market geography for each segment for the three and nine months ended January 24, 2020 and January 25, 2019:


	U.S.⁽¹⁾⁽⁴⁾						Non-U.S. Developed Markets⁽²⁾⁽⁴⁾						Emerging Markets⁽³⁾⁽⁴⁾
	Three months ended						Three months ended						Three months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cardiac and Vascular Group	$	1,366	$	1,369	$	915	$	924	$	538	$	493
Minimally Invasive Therapies Group	934		930		791		796		451		398
Restorative Therapies Group	1,409		1,354		436		435		266		237
Diabetes Group	312		348		236		213		63		49
Total	$	4,021	$	4,001	$	2,377	$	2,368	$	1,318	$	1,177

	U.S.⁽¹⁾⁽⁴⁾						Non-U.S. Developed Markets⁽²⁾⁽⁴⁾						Emerging Markets⁽³⁾⁽⁴⁾
	Nine months ended						Nine months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cardiac and Vascular Group	$	4,182	$	4,240	$	2,735	$	2,766	$	1,547	$	1,449
Minimally Invasive Therapies Group	2,769		2,659		2,364		2,396		1,285		1,168
Restorative Therapies Group	4,187		4,005		1,278		1,275		770		688
Diabetes Group	930		1,006		693		619		176		140
Total	$	12,068	$	11,910	$	7,069	$	7,056	$	3,778	$	3,445

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

(4)Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases of revenue. At January 24, 2020, $862 million of rebates were classified as other accrued expenses and $447 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. At April 26, 2019, $764 million of rebates were classified as other accrued expenses and $432 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. The Company includes obligations for returns in other accrued expenses in the consolidated balance sheets and the right-of-return asset in other current assets in the consolidated balance sheets. The right-of-return asset and liability at January 24, 2020 and April 26, 2019 were not material. For the three and nine months ended January 24, 2020 and January 25, 2019, adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were not material.

Deferred Revenue and Remaining Performance Obligations

The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue at January 24, 2020 and April 26, 2019 was $303 million and $315 million, respectively. At January 24, 2020 and April 26, 2019, $212 million and $211 million, respectively, was included in other accrued expenses and $91 million and $104 million, respectively, was included in other liabilities. During the nine months ended January 24, 2020, the Company recognized $192 million of revenue that was included in deferred revenue as of April 26, 2019.

Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At January 24, 2020, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $1.2 billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next four years.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

4. Acquisitions

The Company had acquisitions during the nine months ended January 24, 2020 and January 25, 2019 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the consolidated results of the Company for the three and nine months ended January 24, 2020 and January 25, 2019. The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired.

Fiscal Year 2020

The acquisition date fair value of net assets acquired during the nine months ended January 24, 2020 was $272 million, consisting of $324 million of assets acquired and $52 million of liabilities assumed. Based upon preliminary valuations, assets acquired were primarily comprised of $139 million of technology-based intangible assets and $26 million of customer-related intangible assets with estimated useful lives ranging from 8 to 16 years, $92 million of goodwill, and $40 million of inventory. The goodwill is not deductible for tax purposes. The Company recognized $65 million of contingent consideration liabilities in connection with business combinations during the nine months ended January 24, 2020, which are comprised of revenue milestone-based payments. For the nine months ended January 24, 2020, purchase price allocation adjustments for fiscal year 2020 business combinations were not significant.

Fiscal Year 2019

Mazor Robotics

On December 18, 2018, the Company's Restorative Therapies Group acquired Mazor Robotics (Mazor), a pioneer in the field of robotic guidance systems. The acquisition of Mazor strengthened the Company's position as a global leader in enabling technologies for spine surgery. The Company offers a fully-integrated procedural solution for surgical planning, execution and confirmation by combining the Company's spine implants, navigation, and intra-operative imaging technology with Mazor's robotic-assisted surgery systems. Total consideration for the transaction, net of cash acquired, was $1.6 billion, consisting of $1.3 billion of cash and $246 million of a previously-held equity investment in Mazor. Net assets acquired includes $383 million of technology-based intangible assets and $16 million of tradenames with estimated useful lives of 10 years. Goodwill was primarily attributable to pull-through revenue, future yet to be defined technologies, and an assembled workforce and was not deductible for tax purposes.

During the three and nine months ended January 25, 2019, the Company recognized $51 million of costs incurred in connection with the acquisition of Mazor, including payouts for unvested stock options and investment banker and other transaction fees, which were recognized in selling, general, and administrative expense in the consolidated statements of income.

The Company made certain adjustments to the allocation of purchase price for the Mazor acquisition during the fourth quarter of fiscal year 2019 and nine months ended January 24, 2020, primarily related to estimates for certain contingent liabilities and deferred taxes, which resulted in a net increase to goodwill of $105 million. The measurement period for the Mazor acquisition closed during the quarter ended January 24, 2020.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The fair values of the assets acquired and liabilities assumed were as follows:


(in millions)	Mazor Robotics
Cash and cash equivalents	$	109
Investments	52
Accounts receivable	9
Inventory	5
Other current assets	1
Property, plant, and equipment	3
Goodwill	1,318
Other intangible assets	399
Tax assets	9
Total assets acquired	1,905

Current liabilities	210

Deferred tax liabilities	21
Total liabilities assumed	231
Net assets acquired	$	1,674

Other Fiscal Year 2019 Acquisitions

The remaining acquisition date fair value of net assets acquired during the nine months ended January 25, 2019 was $377 million, consisting of $427 million of assets acquired and $50 million of liabilities assumed. Assets acquired were primarily comprised of $146 million of goodwill, $161 million of technology-based intangible assets with estimated useful lives ranging from 4 to 15 years, and $40 million of customer-related intangible assets with estimated useful lives ranging from 10 to 13 years. The Company recognized $51 million of contingent consideration liabilities in connection with business combinations during the nine months ended January 25, 2019. For the nine months ended January 25, 2019, purchase price allocation adjustments were not significant.

Acquired In-Process Research & Development

In-process research and development (IPR&D) acquired outside of a business combination is expensed immediately. During the three and nine months ended January 25, 2019, the Company acquired $15 million of IPR&D in connection with an asset acquisition, which was recognized in other operating (income) expense, net in the consolidated statements of income. The Company did not acquire any IPR&D in connection with an asset acquisition during the three and nine months ended January 24, 2020.

Contingent Consideration

Certain of the Company’s business combinations and intangible asset acquisitions involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating (income) expense, net in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.

The fair value of contingent consideration at January 24, 2020 and April 26, 2019 was $304 million and $222 million, respectively. At January 24, 2020, $147 million was recorded in other accrued expenses and $157 million was recorded in other liabilities in the consolidated balance sheets. At April 26, 2019, $73 million was recorded in other accrued expenses and $149 million was recorded in other liabilities in the consolidated balance sheets.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Beginning balance	$	260	$	203	$	222	$	173
Purchase price contingent consideration	45		5		110		51
Payments	(3)		(1)		(32)		(8)
Change in fair value	2		(59)		4		(68)
Ending balance	$	304	$	148	$	304	$	148

The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based consideration). Projected revenues are based on the Company's most recent internal operational budgets and long-range strategic plans. Changes in projected payment dates, discount rates, probabilities of payment, and projected revenues may result in adjustments to the fair value measurement. The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:

Fair Value at

(in millions)

January 24, 2020

Valuation Technique

Unobservable Input

Range

Discount rate

11.5% - 32.5%

Revenue and other performance-based payments

$123

Discounted cash flow

Probability of payment

30% - 100%

Projected fiscal year of payment

2020 - 2026

Discount rate

5.5%

Product development and other milestone-based payments

$181

Discounted cash flow

Probability of payment

75% - 100%

Projected fiscal year of payment

2020 - 2027

5. Restructuring

In the third quarter of fiscal year 2018, the Company announced its Enterprise Excellence restructuring program, which is expected to leverage the Company's global size and scale, as well as enhance the customer and employee experience, with a focus on three objectives: global operations, functional optimization, and commercial optimization. Primary activities of the restructuring program include integrating and enhancing global manufacturing and supply processes, systems and site presence, enhancing and leveraging global operating models across several enabling functions, and optimizing certain commercial processes, systems, and models.

The Company estimates that, in connection with its Enterprise Excellence restructuring program, it will recognize pre-tax exit and disposal costs and other costs across all segments of approximately $1.6 billion to $1.8 billion, the majority of which are expected to be incurred by the end of fiscal year 2022. Approximately half of the estimated charges are related to employee termination benefits. The remaining charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income.

For the three and nine months ended January 24, 2020, the Company recognized charges of $97 million and $328 million, respectively. Additionally, the Company incurred accrual adjustments of $13 million for the nine months ended January 24, 2020, related to certain employees identified for termination finding other positions within Medtronic. For the three and nine months ended January 24, 2020, charges included $50 million and $117 million, respectively, recognized within cost of products sold and $34 million and $111 million, respectively, recognized within selling, general, and administrative expense in the consolidated statements of income.

For the three and nine months ended January 25, 2019, the Company recognized charges of $69 million and $264 million, respectively. Additionally, the Company incurred accrual adjustments of $3 million and $8 million for the three and nine months ended January 25, 2019, respectively, related to certain employees identified for termination finding other positions within Medtronic. For the three and nine months ended January 25, 2019, charges included $21 million and $58 million,

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

respectively, recognized within cost of products sold and $19 million and $86 million, respectively, recognized within selling, general, and administrative expense in the consolidated statements of income.

The following table summarizes the activity related to the Enterprise Excellence restructuring program for the nine months ended January 24, 2020:


(in millions)	Employee Termination Benefits		Associated Costs⁽¹⁾		Asset Write-Downs⁽²⁾		Other Costs		Total
April 26, 2019	$	101	$	9	$	—	$	12	$	122
Charges	91		223		6		8		328
Cash payments	(118)		(223)		—		(8)		(349)
Settled non-cash	—		—		(6)		—		(6)
Accrual adjustments	(5)		—		—		(8)		(13)
January 24, 2020	$	69	$	9	$	—	$	4	$	82

(1)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.

(2)Recognized within cost of products sold in the consolidated statements of income.

6. Financial Instruments

Debt Securities

The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at January 24, 2020 and April 26, 2019:


	January 24, 2020
	Valuation												Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses		Fair Value		Investments		Other Assets
Level 1:
U.S. government and agency securities	$	623	$	17	$	—	$	640	$	640	$	—
Level 2:
Corporate debt securities	5,155		52		(8)		5,199		5,199		—
U.S. government and agency securities	900		—		—		900		900		—
Mortgage-backed securities	655		13		(13)		655		655		—
Non-U.S. government and agency securities	13		—		—		13		13		—
Other asset-backed securities	511		3		(2)		512		512		—
Total Level 2	7,234		68		(23)		7,279		7,279		—
Level 3:

Auction rate securities	36		—		(3)		33		—		33

Total available-for-sale debt securities	$	7,893	$	85	$	(26)	$	7,952	$	7,919	$	33

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)


	April 26, 2019
	Valuation												Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses		Fair Value		Investments		Other Assets
Level 1:
U.S. government and agency securities	$	529	$	1	$	(7)	$	523	$	523	$	—
Level 2:
Corporate debt securities	3,500		14		(21)		3,493		3,493		—
U.S. government and agency securities	387		1		(7)		381		381		—
Mortgage-backed securities	537		3		(20)		520		520		—
Non-U.S. government and agency securities	11		—		—		11		11		—
Other asset-backed securities	529		1		(3)		527		527		—
Total Level 2	4,964		19		(51)		4,932		4,932		—
Level 3:
Auction rate securities	47		—		(3)		44		—		44
Total available-for-sale debt securities	$	5,540	$	20	$	(61)	$	5,499	$	5,455	$	44

The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at January 24, 2020 and April 26, 2019:


	January 24, 2020
	Less than 12 months						More than 12 months
(in millions)	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
U.S. government and agency securities	$	96	$	—	$	40	$	—
Corporate debt securities	371		(3)		65		(5)
Mortgage-backed securities	82		(1)		63		(12)

Other asset-backed securities	23		—		165		(2)
Auction rate securities	—		—		33		(3)
Total	$	572	$	(4)	$	366	$	(22)


	April 26, 2019
	Less than 12 months						More than 12 months
(in millions)	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
U.S. government and agency securities	$	130	$	(1)	$	649	$	(13)
Corporate debt securities	582		(5)		1,153		(16)
Mortgage-backed securities	73		(1)		250		(19)

Other asset-backed securities	290		(2)		85		(1)
Auction rate securities	—		—		44		(3)
Total	$	1,075	$	(9)	$	2,181	$	(52)

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and nine months ended January 24, 2020 and January 25, 2019. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

During the three and nine months ended January 24, 2020, the Company redeemed $11 million worth of level 3 investments at par value. No gain or loss was recognized on the redemption. There were no purchases, sales, settlements, or gains or losses recognized in earnings or other comprehensive income for available-for-sale securities classified as Level 3 during the three and nine months ended January 25, 2019.

Activity related to the Company’s debt securities portfolio is as follows:


	Three months ended						Nine months Ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Proceeds from sales	$	2,531	$	1,301	$	5,789	$	3,217
Gross realized gains	9		9		17		17
Gross realized losses	(2)		(36)		(13)		(55)

Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. At January 24, 2020 and April 26, 2019, the credit loss portion of other-than-temporary impairments on debt securities was not significant. No available-for-sale securities were sold for significantly less than carrying value during the three and nine months ended January 24, 2020 and January 25, 2019.

The January 24, 2020 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.


(in millions)	January 24, 2020
Due in one year or less	$	3,595
Due after one year through five years	2,727
Due after five years through ten years	1,577
Due after ten years	53
Total	$	7,952

Equity Securities, Equity Method Investments, and Other Investments

The Company holds investments in equity securities with and without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments and investments without readily determinable fair values are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data.

The following table summarizes the Company's equity and other investments at January 24, 2020 and April 26, 2019, which are classified as other assets in the consolidated balance sheets:


(in millions)	January 24, 2020		April 26, 2019
Investments with readily determinable fair value (marketable equity securities)	$	39	$	—
Investments without readily determinable fair values	373		308
Equity method and other investments	68		64
Total equity and other investments	$	480	$	372

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income.


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Proceeds from sales	$	—	$	33	$	2	$	941
Gross gains	1		8		16		131
Gross losses	—		(1)		—		(30)
Impairment losses recognized	(1)		—		(5)		(12)

Net gains recognized for the three and nine months ended January 24, 2020 were $1 million and $16 million, respectively, comprised of unrealized gains on equity and other investments still held at January 24, 2020. Net gains recognized during the three months ended January 25, 2019 were $7 million, comprised of $1 million net realized gains on equity and other investments sold during the period and $6 million of net unrealized gains on equity and other investments still held at January 25, 2019. Net gains recognized during the nine months ended January 25, 2019 were $101 million, comprised of $71 million of net realized gains on equity and other investments sold during the period and $30 million of net unrealized gains on equity and other investments still held at January 25, 2019.

7. Financing Arrangements

Commercial Paper

The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. No commercial paper was outstanding at both January 24, 2020 and April 26, 2019. The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below.

Line of Credit

The Company has a $3.5 billion five-year unsecured revolving credit facility (Credit Facility) which provides back-up funding for the commercial paper program described above. At January 24, 2020 and April 26, 2019, no amounts were outstanding under the Credit Facility.

Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreement also contains customary covenants, all of which the Company was in compliance with at January 24, 2020.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Debt Obligations

The Company's debt obligations consisted of the following:


(in millions)	Maturity by Fiscal Year	January 24, 2020		April 26, 2019
Current debt obligations	2020 - 2021	$	844	$	838

Long-term debt
0.000 percent two-year 2019 senior notes	2021	1,662		1,681
Floating rate two-year 2019 senior notes	2021	831		560
4.125 percent ten-year 2011 senior notes	2021	—		500
3.150 percent seven-year 2015 senior notes	2022	1,534		2,500
3.125 percent ten-year 2012 senior notes	2022	—		675
3.200 percent ten-year 2012 CIFSA senior notes	2023	650		650
0.375 percent four-year 2019 senior notes	2023	1,662		1,681
2.750 percent ten-year 2013 senior notes	2023	530		530
0.000 percent four-year 2019 senior notes	2023	831		—
2.950 percent ten-year 2013 CIFSA senior notes	2024	310		310
3.625 percent ten-year 2014 senior notes	2024	432		850
3.500 percent ten-year 2015 senior notes	2025	2,700		4,000
0.250 percent seven-year 2019 senior notes	2026	1,108		—
1.125 percent eight-year 2019 senior notes	2027	1,662		1,681
3.350 percent ten-year 2017 senior notes	2027	368		850
1.625 percent twelve-year 2019 senior notes	2031	1,108		1,121
1.000 percent thirteen-year 2019 senior notes	2032	1,108		—
4.375 percent twenty-year 2015 senior notes	2035	1,931		2,382
6.550 percent thirty-year 2007 CIFSA senior notes	2038	253		284
2.250 percent twenty-year 2019 senior notes	2039	1,108		1,121
6.500 percent thirty-year 2009 senior notes	2039	158		183
5.550 percent thirty-year 2010 senior notes	2040	224		306
1.500 percent twenty-year 2019 senior notes	2040	1,108		—
4.500 percent thirty-year 2012 senior notes	2042	105		129
4.000 percent thirty-year 2013 senior notes	2043	305		325
4.625 percent thirty-year 2014 senior notes	2044	127		177
4.625 percent thirty-year 2015 senior notes	2045	1,813		1,963
1.750 percent thirty-year 2019 senior notes	2050	1,108		—
Bank borrowings	2021 - 2022	70		83
Debt (discount) premium, net	2020 - 2050	(15)		29
Finance lease obligations	2021 - 2033	47		10
Interest rate swaps	N/A	—		9
Deferred financing costs	2020 - 2050	(106)		(104)
Long-term debt		$	24,732	$	24,486

Senior Notes

The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at January 24, 2020.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

In June 2019, Medtronic Luxco issued six tranches of Euro-denominated Senior Notes with an aggregate principal of €5.0 billion, with maturities ranging from fiscal year 2021 to fiscal year 2050, resulting in cash proceeds of approximately $5.6 billion, net of discounts and issuance costs. The issuance included €250 million of floating rate Senior Notes due in fiscal year 2021, €750 million of 0.000 percent Senior Notes due in fiscal year 2023, €1.0 billion of 0.250 percent Senior Notes due in fiscal year 2026, €1.0 billion of 1.000 percent Senior Notes due in fiscal year 2032, €1.0 billion of 1.500 percent Senior Notes due in fiscal year 2040, and €1.0 billion of 1.750 percent Senior Notes due in fiscal year 2050. The Company used the net proceeds of the offering to fund the cash tender offer and early redemption, described below. The Euro-denominated debt is designated as a net investment hedge of certain of the Company's European operations. Refer to Note 8 for additional information regarding the net investment hedge.

The Company completed the cash tender offer of $4.6 billion of Medtronic Inc., CIFSA, and Medtronic Luxco Senior Notes for $5.0 billion of total consideration in July 2019. The Company recognized a loss on debt extinguishment of $413 million during the first quarter of fiscal year 2020, which primarily included cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss on debt extinguishment also included a $16 million charge for the estimated early redemption premium for $533 million of senior notes which were redeemed in August 2019. The loss on debt extinguishment was recognized in interest expense in the consolidated statements of income.

Financial Instruments Not Measured at Fair Value

At January 24, 2020, the estimated fair value of the Company’s Senior Notes was $27.5 billion compared to a principal value of $25.2 billion. At April 26, 2019, the estimated fair value was $26.2 billion compared to a principal value of $25.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

8. Derivatives and Currency Exchange Risk Management

The Company uses operational and economic hedges, including currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro, Japanese Yen, and British Pound. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $12.1 billion and $11.1 billion at January 24, 2020 and April 26, 2019, respectively.

The Company also uses derivative and non-derivative instruments to manage the impact of currency exchange rate changes on net investments in foreign currency-denominated operations. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets and statements of income.

Freestanding Derivative Contracts

Freestanding derivative contracts are primarily used to offset the Company’s exposure to the change in value of specific foreign-currency-denominated assets and liabilities, and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. The gross notional amount of the Company's freestanding currency exchange rate contracts outstanding at January 24, 2020 and April 26, 2019 was $5.2 billion and $4.3 billion, respectively. The Company's freestanding currency exchange rate contracts are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign-currency-denominated assets, liabilities, and cash flows.

The Company also uses total return swaps to hedge the liability of a non-qualified, deferred compensation plan. The gross notional amount of the Company's total return swaps outstanding at January 24, 2020 and April 26, 2019 was $215 million and $191 million, respectively. The Company's total return swaps are not designated as hedges, and therefore, changes in the value of these instruments are recognized in earnings. The cash flows related to the Company's freestanding derivative contracts are reported as operating activities in the consolidated statements of cash flows.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The amounts and classification of the (gains) losses in the consolidated statements of income related to derivative instruments not designated as hedging instruments for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows:


		Three months ended						Nine months ended
(in millions)	Classification	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Currency exchange rate contracts	Other operating (income) expense, net	$	2	$	30	$	(4)	$	(171)
Total return swaps	Other operating (income) expense, net	(17)		—		(22)		—
Total		$	(15)	$	30	$	(26)	$	(171)

Cash Flow Hedges

Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. The gross notional amount of these contracts, designated as cash flow hedges, outstanding at January 24, 2020 and April 26, 2019 was $6.9 billion and $6.8 billion, respectively, and will mature within the subsequent two-year period. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss. The gain or loss on the derivative instrument is reclassified into earnings and is included in other operating (income) expense, net in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings in the current period. The cash flows related to all of the Company's derivative instruments designated as cash flow hedges are reported as operating activities in the consolidated statements of cash flows. No components of the hedge contracts were excluded in the measurement of hedge effectiveness, and no forward contracts designated as cash flow hedges were derecognized or discontinued during the three and nine months ended January 24, 2020 and January 25, 2019.

The amount of the (gains) losses recognized in AOCI related to the currency exchange rate contract derivative instruments designated as cash flow hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows:


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Currency exchange rate contracts	$	(41)	$	(25)	$	(144)	$	(469)

The amount of the (gains) losses recognized in the consolidated statements of income related to derivative instruments designated as cash flow hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows:


	Three months ended						Nine months ended
	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
(in millions)	Other operating (income) expense, net		Other operating (income) expense, net		Other operating (income) expense, net		Other operating (income) expense, net
Total amounts of income and expense line items presented in the consolidated statements of income in which the effects of cash flow hedges are recorded	$	(39)	$	57	$	88	$	278



Currency exchange rate contracts designated as cash flow hedges:
Amount of (gain) loss reclassified from AOCI into income	(82)		(48)		(206)		(56)

Forecasted Debt Issuance Interest Rate Risk

Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. The gains or losses on forward starting interest rate derivative instruments that are designated and qualify as cash flow hedges are reported as a component of accumulated other comprehensive loss. Beginning in the period in which the planned debt issuance occurs and the related derivative instruments are terminated, the gains or losses are then reclassified into interest expense over the term of the related debt. For the three and

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

nine months ended January 24, 2020 and January 25, 2019, the reclassifications of net (gains) losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense were not significant.

At January 24, 2020 and April 26, 2019 the Company had $157 million and $194 million, respectively, in after-tax net unrealized gains associated with cash flow hedging instruments recorded in accumulated other comprehensive loss. The Company expects that $145 million of after-tax net unrealized gains at January 24, 2020 will be recognized in the consolidated statements of income over the next 12 months.

Fair Value Hedges

Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount.

Changes in the fair value of the derivative instrument are recognized in interest expense and are offset by changes in the fair value of the underlying debt instrument. The gains from terminated interest rate swap agreements are recognized in long-term debt, increasing the outstanding balances of the debt, and amortized as a reduction of interest expense over the remaining life of the related debt. The cash flows related to the Company's interest rate derivative instruments designated as fair value hedges are reported as operating activities in the consolidated statements of cash flows.

At January 24, 2020 the Company had no interest rate swaps outstanding designated as fair value hedges, as the Company terminated previously held swaps in connection with the tender and early redemption of the underlying senior notes during the first quarter of fiscal year 2020. At April 26, 2019, the Company had interest rate swaps in gross notional amounts of $1.2 billion, designated as fair value hedges of underlying fixed-rate senior note obligations, including the Company's $500 million 4.125 percent 2011 Senior Notes due fiscal year 2021 and the $675 million 3.125 percent 2012 Senior Notes due fiscal year 2022.

The gain recognized upon termination of interest rate swaps was not significant for the three and nine months ended January 24, 2020. At April 26, 2019, the market value of outstanding interest rate swap agreements was an unrealized gain of $9 million which was recorded in other assets, with the offset recorded in long-term debt on the consolidated balance sheets. The Company did not recognize any gains or losses during the three or nine months ended January 24, 2020 and January 25, 2019 on firm commitments that no longer qualify as fair value hedges.

The following amounts were recorded on the consolidated balance sheet related to the cumulative basis adjustments for fair value hedges:


(in millions)	Carrying Amount of Hedged Assets/(Liabilities)						Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities)
Location on the Consolidated Balance Sheet	January 24, 2020		April 26, 2019		January 24, 2020		April 26, 2019
Long-term debt	$	—	$	(1,175)	$	—	$	9

Net Investment Hedges

The Company has designated Euro-denominated debt as a net investment hedge of certain of its European operations to manage the exposure to currency and exchange rate movements for foreign currency-denominated net investments in foreign operations. At January 24, 2020, the Company had €12.0 billion, or $13.3 billion, of outstanding Euro-denominated debt designated as a hedge of its net investment in certain of its European operations, which will mature in fiscal years 2021 through 2050.

Additionally, during the first quarter of fiscal year 2020, the Company entered into and settled forward currency exchange rate contracts to manage the exposure to exchange rate movements in anticipation of the issuance of Euro-denominated senior notes. Certain of these forward currency exchange rate contracts were designated as a net investment hedge of certain of the Company's European operations. These contracts matured in conjunction with the issuance of Euro-denominated debt in the first quarter of fiscal year 2020.

For instruments that are designated and qualify as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in other

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

operating (income) expense, net. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows.

At January 24, 2020 and April 26, 2019 the Company had $18 million in after-tax unrealized gains, and $169 million in after-tax unrealized losses, respectively, associated with net investment hedges recorded in accumulated other comprehensive loss. The Company does not expect any of the after-tax unrealized gains at January 24, 2020 to be recognized in the consolidated statements of income over the next 12 months.

The Company did not recognize any gains or losses during the three or nine months ended January 24, 2020 or January 25, 2019 on instruments that no longer qualify as net investment hedges.

The amount and classifications of the (gains) losses recognized in the consolidated statements of income for the portion of the net investment hedges excluded from the measurement of hedge effectiveness were as follows:


		Three months ended						Nine months ended
(in millions)	Classification	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Net investment hedges	Other operating (income) expense, net	$	—	$	—	$	(7)	$	—

The amount of the (gains) losses recognized in AOCI related to instruments designated as net investment hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows:


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Net investment hedges	$	(35)	$	—	$	(187)	$	—

Balance Sheet Presentation

The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at January 24, 2020 and April 26, 2019. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories.


	January 24, 2020
	Derivative Assets				Derivative Liabilities
(in millions)	Balance Sheet Classification	Fair Value		Balance Sheet Classification	Fair Value
Derivatives designated as hedging instruments
Currency exchange rate contracts	Other current assets	$	183	Other accrued expenses	$	11

Currency exchange rate contracts	Other assets	75		Other liabilities	12
Total derivatives designated as hedging instruments		258			23
Derivatives not designated as hedging instruments
Currency exchange rate contracts	Other current assets	9		Other accrued expenses	10
Total return swap	Other current assets	16		Other accrued expenses	—
Cross currency interest rate contracts	Other current assets	1		Other accrued expenses	—


Total derivatives not designated as hedging instruments		26			10
Total derivatives		$	284		$	33

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)


	April 26, 2019
	Derivative Assets				Derivative Liabilities
(in millions)	Balance Sheet Classification	Fair Value		Balance Sheet Classification	Fair Value
Derivatives designated as hedging instruments
Currency exchange rate contracts	Other current assets	$	234	Other accrued expenses	$	1
Interest rate contracts	Other assets	9		Other liabilities	—
Currency exchange rate contracts	Other assets	78		Other liabilities	1
Total derivatives designated as hedging instruments		321			2
Derivatives not designated as hedging instruments
Currency exchange rate contracts	Other current assets	23		Other accrued expenses	17
Total return swaps	Other current assets	15		Other accrued expenses	—
Cross currency interest rate contracts	Other current assets	6		Other accrued expenses	—

Total derivatives not designated as hedging instruments		44			17
Total derivatives		$	365		$	19

The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis.


	January 24, 2020						April 26, 2019
(in millions)	Level 1		Level 2		Level 1		Level 2
Derivative assets	$	267	$	17	$	335	$	30
Derivative liabilities	33		—		19		—

The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.

The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.


	January 24, 2020
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recorded Assets (Liabilities)		Financial Instruments		Cash Collateral Posted (Received)		Net Amount
Derivative assets:
Currency exchange rate contracts	$	267	$	(33)	$	(5)	$	229

Total return swaps	16		—		—		16
Cross currency interest rate contracts	1		—		—		1
	284		(33)		(5)		246
Derivative liabilities:
Currency exchange rate contracts	(33)		33		—		—



	(33)		33		—		—
Total	$	251	$	—	$	(5)	$	246

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)


	April 26, 2019
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recorded Assets (Liabilities)		Financial Instruments		Cash Collateral Posted (Received)		Net Amount
Derivative assets:
Currency exchange rate contracts	$	335	$	(9)	$	(43)	$	283
Interest rate contracts	9		—		(1)		8
Total return swaps	15		—		—		15

Cross currency interest rate contracts	6		—		—		6
	365		(9)		(44)		312
Derivative liabilities:
Currency exchange rate contracts	(19)		9		—		(10)



	(19)		9		—		(10)
Total	$	346	$	—	$	(44)	$	302

9. Inventories

Inventory balances, net of reserves, were as follows:


(in millions)	January 24, 2020		April 26, 2019
Finished goods	$	2,693	$	2,476
Work in-process	643		572
Raw materials	786		705
Total	$	4,122	$	3,753

10. Goodwill and Other Intangible Assets

Goodwill

The following table presents the changes in the carrying amount of goodwill by segment:


(in millions)	Cardiac and Vascular Group		Minimally Invasive Therapies Group		Restorative Therapies Group		Diabetes Group		Total
April 26, 2019	$	6,854	$	20,381	$	10,821	$	1,903	$	39,959
Goodwill as a result of acquisitions	—		11		65		16		92
Purchase accounting adjustments	7		2		119		(5)		123
Currency translation and other	5		(59)		(29)		—		(83)
January 24, 2020	$	6,866	$	20,335	$	10,976	$	1,914	$	40,091

The Company assesses goodwill for impairment annually as of the first day of the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did not recognize any goodwill impairment during the three and nine months ended January 24, 2020 or January 25, 2019.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:


	January 24, 2020						April 26, 2019
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,971	$	(4,824)	$	16,944	$	(4,095)
Purchased technology and patents	10,640		(4,178)		11,405		(4,570)
Trademarks and tradenames	464		(228)		570		(324)
Other	83		(54)		85		(59)
Total	$	28,158	$	(9,284)	$	29,004	$	(9,048)
Indefinite-lived:
IPR&D	$	582	$	—	$	604	$	—

The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying value of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not recognize any definite-lived intangible asset charges during the three months ended January 24, 2020. During the nine months ended January 24, 2020, the Company recognized $33 million of definite-lived intangible asset charges in connection with the exit of businesses within the Restorative Therapies Group segment. During the three months ended January 25, 2019, the Company recognized $26 million of definite-lived intangible asset charges in connection with business exits within the Restorative Therapies Group segment. During the nine months ended January 25, 2019, the Company recognized $87 million of definite-lived intangible asset charges, including $26 million and $61 million of charges in connection with business exits within the Restorative Therapies Group and Cardiac and Vascular Group segments, respectively. Definite-lived intangible asset impairment charges are recognized in other operating (income) expense, net in the consolidated statements of income.

The Company assesses indefinite-lived intangibles for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying value may be impaired. The Company did not recognize any indefinite-lived intangible asset impairments during the three and nine months ended January 24, 2020. During the three and nine months ended January 25, 2019, the Company recognized $21 million of indefinite-lived intangible asset charges, including $11 million in connection with a business exit within the Restorative Therapies Group segment. Indefinite-lived intangible asset charges are recognized in other operating (income) expense, net in the consolidated statements of income. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.

Amortization Expense

Intangible asset amortization expense for the three and nine months ended January 24, 2020 and January 25, 2019 was $436 million and $1.3 billion, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at January 24, 2020, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:


(in millions)	Amortization Expense
Remaining 2020	$	437
2021	1,741
2022	1,699
2023	1,634
2024	1,605
2025	1,576

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

11. Income Taxes

The Company's effective tax rate for the three and nine months ended January 24, 2020 was (21.5) percent and (8.2) percent, respectively, as compared to 7.2 percent and 11.2 percent for the three and nine months ended January 25, 2019, respectively. The decrease in the effective tax rate for the three and nine months ended January 24, 2020, as compared to the corresponding periods in the prior fiscal year, was primarily due to the impact of certain tax adjustments described below.

Certain Tax Adjustments

During the three months ended January 24, 2020, the benefit from certain tax adjustments of $558 million, recognized in income tax provision in the consolidated statements of income, included the following:

•A benefit of $558 million related to the release of a valuation allowance previously recorded against certain net operating losses. Luxembourg enacted tax legislation during the quarter which required the Company to reassess the realizability of certain net operating losses. The Company evaluated both the positive and negative evidence and released valuation allowance equal to the expected benefit from the utilization of certain net operating losses in connection with a planned intercompany sale of intellectual property.

During the nine months ended January 24, 2020, the net benefit from certain tax adjustments of $839 million, recognized in income tax provision in the consolidated statements of income, included the following:

•A net benefit of $30 million related to U.S. Treasury’s issuance of certain Final Regulations associated with U.S. Tax Reform. The primary impact of these regulations resulted in the Company re-establishing its permanently reinvested assertion on certain foreign earnings and reversing the previously accrued tax liability. This benefit was partially offset by additional tax associated with a previously executed internal reorganization of certain foreign subsidiaries.

•A benefit of $251 million related to tax legislative changes in Switzerland which abolished certain preferential tax regimes the Company benefited from and replaced them with a new set of internationally accepted measures. The legislation provided for higher effective tax rates but allowed for a transitional period whereby an amortizable asset was created for Swiss federal income tax purposes which will be amortized and deducted over a 10-year period.

During the three months ended January 25, 2019, the net benefit from certain tax adjustments of $64 million, recognized in income tax provision in the consolidated statements of income, included the following:

•A net benefit of $12 million associated with the transition tax liability and the impacts of U.S. Tax Reform on deferred tax assets, liabilities, and valuation allowances.

•A benefit of $32 million related to intercompany legal entity restructuring.

•A net benefit of $20 million associated with the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses.

During the nine months ended January 25, 2019, the net benefit from certain tax adjustments of $35 million, recognized in income tax provision in the consolidated statements of income, included the following:

•A net benefit of $25 million associated with the transition tax liability and the impacts of U.S. Tax Reform on deferred tax assets, liabilities, and valuation allowances

•A benefit of $32 million related to intercompany legal entity restructuring.

•A net benefit of $20 million associated with the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

•A charge of $42 million related to the recognition of a prepaid tax expense resulting from the reduction in the U.S. statutory tax rate due to U.S. Tax Reform and the sale of U.S. manufactured inventory held as of April 27, 2018.

At January 24, 2020 and April 26, 2019, the Company's gross unrecognized tax benefits were $1.8 billion. In addition, the Company had accrued gross interest and penalties of $207 million at January 24, 2020. If all of the Company’s unrecognized tax benefits were recognized, approximately $1.8 billion would impact the Company’s effective tax rate. At both January 24, 2020 and April 26, 2019, the total balance of the Company's gross unrecognized tax benefits was recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets.

Refer to Note 17 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

12. Earnings Per Share

Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

The table below sets forth the computation of basic and diluted earnings per share:


	Three months ended						Nine months ended
(in millions, except per share data)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Numerator:
Net income attributable to ordinary shareholders	$	1,915	$	1,269	$	4,143	$	3,459
Denominator:
Basic – weighted average shares outstanding	1,340.5		1,342.8		1,340.7		1,348.1
Effect of dilutive securities:
Employee stock options	8.4		6.9		7.8		7.9
Employee restricted stock units	2.6		3.0		2.9		3.2
Other	—		—		0.2		0.3
Diluted – weighted average shares outstanding	1,351.5		1,352.7		1,351.6		1,359.5

Basic earnings per share	$	1.43	$	0.95	$	3.09	$	2.57
Diluted earnings per share	$	1.42	$	0.94	$	3.07	$	2.54

The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 3 million ordinary shares for both the three and nine months ended January 24, 2020, and 7 million ordinary shares for both the three and nine months ended January 25, 2019, because their effect would have been anti-dilutive on the Company’s earnings per share.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

13. Stock-Based Compensation

The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and nine months ended January 24, 2020 and January 25, 2019:


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Stock options	$	12	$	11	$	52	$	62
Restricted stock	46		43		159		144
Employee stock purchase plan	8		6		24		22
Total stock-based compensation expense	$	66	$	60	$	235	$	228

Cost of products sold	$	6	$	5	$	22	$	23
Research and development expense	9		8		29		29
Selling, general, and administrative expense	51		47		184		176
Total stock-based compensation expense	66		60		235		228
Income tax benefits	(11)		(8)		(40)		(40)
Total stock-based compensation expense, net of tax	$	55	$	52	$	195	$	188

14. Retirement Benefit Plans

The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three months and nine months ended January 24, 2020 and January 25, 2019:


	U.S.						Non-U.S.
	Three months ended						Three months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Service cost	$	26	$	27	$	15	$	15
Interest cost	32		33		7		7
Expected return on plan assets	(56)		(54)		(15)		(14)
Amortization of net actuarial loss	14		19		4		3

Net periodic benefit cost	$	16	$	25	$	11	$	11

	U.S.						Non-U.S.
	Nine months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Service cost	$	78	$	81	$	45	$	45
Interest cost	96		99		21		21
Expected return on plan assets	(168)		(162)		(45)		(42)
Amortization of net actuarial loss	42		57		11		9

Net periodic benefit cost	$	48	$	75	$	32	$	33

Components of net periodic benefit cost other than the service component are recognized in other non-operating income, net in the consolidated statements of income.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

15. Leases

The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease. As the Company’s leases typically do not provide an implicit rate, the Company’s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.

The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for the three and nine months ended January 24, 2020 were not material.

The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases are not material to the consolidated financial statements at or for the three and nine months ended January 24, 2020. Finance lease right-of-use assets are included in property, plant, and equipment, net, and finance lease liabilities are included in current debt obligations and long-term debt on the consolidated balance sheets.

Additionally, from time to time, the Company subleases portions of its real-estate property, resulting in sublease income. Sublease income and the related assets and cash flows were not material to the consolidated financial statements at or for the three and nine months ended January 24, 2020.

The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at January 24, 2020:


(in millions)	Balance Sheet Classification	January 24, 2020

Right-of-use assets	Other assets	$	995
Current liability	Other accrued expenses	169
Non-current liability	Other liabilities	851

The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at January 24, 2020:


						January 24, 2020
Weighted-average remaining lease term						7.5 years



Weighted-average discount rate						3.0%

The following table summarizes the components of total operating lease cost for the three and nine months ended January 24, 2020:


	Three months ended		Nine months ended
(in millions)	January 24, 2020		January 24, 2020
Operating lease cost	$	59	$	170
Short-term lease cost	10		32

Total operating lease cost	$	69	$	202

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for the nine months ended January 24, 2020:


	Nine months ended
(in millions)	January 24, 2020
Cash paid for amounts included in the measurement of operating lease liabilities	$	167
Right-of-use assets obtained in exchange for operating lease liabilities	178

The following table summarizes the maturities of the Company's operating leases at January 24, 2020:


(in millions) Fiscal Year	Operating Leases
Remaining 2020	$	81
2021	203
2022	171
2023	147
2024	125
Thereafter	448
Total expected lease payments	1,175
Less: Imputed interest	(155)
Total lease liability	$	1,020

The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within net sales in the consolidated statements of income and the Company's net investments in sales-type leases are included in other current assets and other assets in the consolidated balance sheets. Lessor income and the related assets and lease maturities were not material to the consolidated financial statements at or for the three and nine months ended January 24, 2020.

As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019, minimum payments under non-cancelable operating leases at April 26, 2019 were:


(in millions) Fiscal Year	Operating Leases
2020	$	216
2021	157
2022	103
2023	61
2024	34
Thereafter	81
Total minimum lease payments	$	652

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

16. Accumulated Other Comprehensive Loss

The following table provides changes in AOCI, net of tax, and by component:


(in millions)	Unrealized (Loss) Gain on Investment Securities		Cumulative Translation Adjustments		Net Investment Hedges		Net Change in Retirement Obligations		Unrealized Gain (Loss) on Cash Flow Hedges		Total Accumulated Other Comprehensive (Loss) Income
April 26, 2019	$	(45)	$	(1,383)	$	(169)	$	(1,308)	$	194	$	(2,711)
Other comprehensive income (loss) before reclassifications	94		(116)		187		(1)		106		270
Reclassifications	(1)		—		—		39		(143)		(105)
Other comprehensive income (loss)	93		(116)		187		38		(37)		165
January 24, 2020	$	48	$	(1,499)	$	18	$	(1,270)	$	157	$	(2,546)


(in millions)	Unrealized (Loss) Gain on Investment Securities		Cumulative Translation Adjustment		Net Investment Hedges		Net Change in Retirement Obligations		Unrealized (Loss) Gain on Cash Flow Hedges		Total Accumulated Other Comprehensive (Loss) Income
April 27, 2018	$	(194)	$	(11)	$	(257)	$	(1,117)	$	(207)	$	(1,786)
Other comprehensive (loss) income before reclassifications	(7)		(1,124)		—		—		353		(778)
Reclassifications	30		—		—		65		(36)		59
Other comprehensive income (loss)	23		(1,124)		—		65		317		(719)
Cumulative effect of change in accounting principle⁽¹⁾	47		—		—		—		—		47
January 25, 2019	$	(124)	$	(1,135)	$	(257)	$	(1,052)	$	110	$	(2,458)

The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during the nine months ended January 24, 2020 and January 25, 2019 was an expense of $7 million and a benefit of $2 million, respectively. During the nine months ended January 24, 2020 and January 25, 2019, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $1 million and $2 million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within other non-operating income, net. Refer to Note 6 to the consolidated financial statements for additional information.

For the nine months ended January 24, 2020, there was no income tax on cumulative translation adjustments. For the nine months ended January 25, 2019, there was a $8 million income tax benefit on cumulative translation adjustments.

During the nine months ended January 24, 2020 and January 25, 2019, there were no tax impacts on net investment hedges. Refer to Note 8 to the consolidated financial statements for additional information.

The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. During the nine months ended January 24, 2020 and January 25, 2019, there were no income tax impacts on the net change in retirement obligations in other comprehensive income before reclassifications. During the nine months ended January 24, 2020 and January 25, 2019, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $9 million and $15 million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within other non-operating income, net. Refer to Note 14 to the consolidated financial statements for additional information.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during the nine months ended January 24, 2020 and January 25, 2019 was an expense of $38 million and $116 million, respectively. During the nine months ended January 24, 2020 and January 25, 2019, gains and losses on cash flow hedges reclassified from AOCI were reduced by income taxes of $47 million and $16 million, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within other operating (income) expense, net, and gains and losses on forward starting interest rate derivatives reclassified from AOCI are recognized within interest expense. Refer to Note 8 to the consolidated financial statements for additional information.

17. Commitments and Contingencies

Legal Matters

The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.

The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies litigation charges and gains related to significant legal matters as certain litigation charges. During the three and nine months ended January 24, 2020, the Company recognized $108 million and $276 million, respectively, of certain litigation charges related to probable and estimable damages for significant legal matters. During the three and nine months ended January 25, 2019, the Company recognized $63 million and $166 million, respectively, of certain litigation charges. At January 24, 2020 and April 26, 2019, accrued litigation was approximately $0.6 billion and $0.5 billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.

Product Liability Matters

Pelvic Mesh Litigation

The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 16,000 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of February 5, 2020, the Company had reached agreements to settle

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

approximately 15,400 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.

Patent Litigation

Ethicon

On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed six of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter.

Sasso

The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately $112 million. The Company has strong arguments to appeal the verdict and has filed post-trial motions and appeals with the appropriate appellate courts. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.

Shareholder Related Matters

Covidien Acquisition

On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstein and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016 the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Environmental Proceedings

The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.

The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills.

The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order.

Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.

Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in fiscal year 2021.

The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above.

Government Matters

Since 2017, the Company has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices relating to a neurovascular product developed and first marketed by ev3 and Covidien. The Company has provided information in response to these requests and is cooperating with the inquiry. The Company has not recognized an expense in connection with any ongoing investigation, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from the ongoing information requests.

Income Taxes

In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings. U.S. Tax Court trial is scheduled to occur in April of 2020.

In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006.

In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006.

In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level.

Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS. The statute of limitations for Covidien's 2016 U.S. federal income tax return lapsed during the third quarter of fiscal year 2020.

While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.

Refer to Note 11 for additional discussion of income taxes.

Guarantees

As a result of the acquisition of Covidien, the Company has a guarantee commitment related to certain contingent tax liabilities as a party to the Tax Sharing Agreement that was entered into on June 29, 2007, between Covidien, Tyco International (now Johnson Controls), and Tyco Electronics (now TE Connectivity), associated with the spin-off from Tyco. The Tax Sharing Agreement covers certain income tax liabilities for periods prior to and including the spin-off. Medtronic’s share of the income tax liabilities for these periods is 42 percent, with Johnson Controls and TE Connectivity share being 27 percent, and 31 percent, respectively. If Johnson Controls and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. The most significant amounts at risk under this Tax Sharing Agreement were resolved with the U.S. Tax Court and IRS Appeals resolutions reached in May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution, including certain state and international tax matters that remain open.

The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to tax years that remain open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or Tyco Electronics legal entities for periods prior to the 2007 separation.

Refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019 for additional information.

As part of the Company’s sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters.

In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.

The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.

18. Segment and Geographic Information

Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. There are certain corporate and centralized expenses that are not allocated to the segments.

The Company’s management evaluates performance of the segments and allocates resources based on segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

to the segments. The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during the first quarter of fiscal year 2020 to remove the impact of non-service pension and post-retirement benefit costs from segment results. This change did not have a material impact on the segment results reviewed. As a result of the change, the Company has revised the disclosure for the prior period to align with the current presentation.

The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment.

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

Net Sales


	Three months ended⁽¹⁾						Nine months ended⁽¹⁾
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cardiac and Vascular Group	$	2,819	$	2,786	$	8,464	$	8,455
Minimally Invasive Therapies Group	2,176		2,124		6,418		6,223
Restorative Therapies Group	2,111		2,026		6,235		5,968
Diabetes Group	610		610		1,798		1,765
Total	$	7,717	$	7,546	$	22,916	$	22,411

(1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Segment Operating Profit


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cardiac and Vascular Group	$	1,101	$	1,076	$	3,284	$	3,262
Minimally Invasive Therapies Group	860		828		2,453		2,396
Restorative Therapies Group	898		824		2,531		2,394
Diabetes Group	158		190		456		538
Segment operating profit	3,017		2,918		8,724		8,590
Interest expense	(156)		(243)		(930)		(726)
Other non-operating income, net	96		71		305		309
Amortization of intangible assets	(436)		(436)		(1,317)		(1,327)
Corporate	(348)		(331)		(1,005)		(974)
Centralized distribution costs	(348)		(383)		(1,117)		(1,313)
Restructuring and associated costs	(97)		(66)		(315)		(256)
Acquisition-related items	(28)		(17)		(74)		(57)
Certain litigation charges	(108)		(63)		(276)		(166)
IPR&D charges	—		(11)		—		(26)
Exit of businesses	—		(69)		(41)		(149)
Debt tender premium and other charges	—		—		7		—
Medical device regulations	(13)		—		(31)		—
Contribution to Medtronic Foundation	—		—		(80)		—

Income before income taxes	$	1,579	$	1,370	$	3,850	$	3,905

Geographic Information

Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three and nine months ended January 24, 2020 and January 25, 2019 for the Company's country of domicile, countries with significant concentrations, and all other countries:


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Ireland	$	22	$	24	$	66	$	68

United States	4,021		4,001		12,068		11,910
Rest of world	3,674		3,521		10,782		10,433
Total other countries, excluding Ireland	7,695		7,522		22,850		22,343
Total	$	7,717	$	7,546	$	22,916	$	22,411

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

19. Guarantor Financial Information

Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Additionally, Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Medtronic Luxco Senior Notes. The following is a summary of these guarantees:

Guarantees of Medtronic Senior Notes

•Parent Company Guarantor - Medtronic plc

•Subsidiary Issuer - Medtronic, Inc.

•Subsidiary Guarantor - Medtronic Luxco

Guarantees of Medtronic Luxco Senior Notes

•Parent Company Guarantor - Medtronic plc

•Subsidiary Issuer - Medtronic Luxco

•Subsidiary Guarantor - Medtronic, Inc.

Guarantees of CIFSA Senior Notes

•Parent Company Guarantor - Medtronic plc

•Subsidiary Issuer - CIFSA

•Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors)

The following presents the Company’s consolidating statements of comprehensive income for the three and nine months ended January 24, 2020 and January 25, 2019, condensed consolidating balance sheets at January 24, 2020 and April 26, 2019, and condensed consolidating statements of cash flows for the nine months ended January 24, 2020 and January 25, 2019. The guarantees provided by the parent company guarantor and subsidiary guarantors are joint and several. Condensed consolidating financial information for Medtronic plc, Medtronic Luxco, Medtronic, Inc., CIFSA, and CIFSA Subsidiary Guarantors, on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.

During the nine months ended January 24, 2020, the Company undertook certain steps to reorganize ownership of various subsidiaries. The transactions were entirely among subsidiaries under the common control of Medtronic. This reorganization has been reflected as of the beginning of the earliest period presented.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Three Months Ended January 24, 2020

Medtronic Senior Notes and Medtronic Luxco Senior Notes


(in millions)	Medtronic plc		Medtronic, Inc.		Medtronic Luxco		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Net sales	$	—	$	344	$	—	$	7,717	$	(344)	$	7,717

Costs and expenses:
Cost of products sold	—		337		—		2,294		(231)		2,400
Research and development expense	—		154		—		419		—		573
Selling, general, and administrative expense	3		432		—		2,152		—		2,587
Amortization of intangible assets	—		6		—		430		—		436
Restructuring charges, net	—		3		—		10		—		13
Certain litigation charges	—		—		—		108		—		108
Other operating expense (income), net	12		(569)		—		624		(106)		(39)
Operating profit (loss)	(15)		(19)		—		1,680		(7)		1,639
Other non-operating (income) expense, net	—		(50)		(174)		(415)		543		(96)
Interest expense	66		316		141		176		(543)		156
Equity in net (income) loss of subsidiaries	(1,994)		(1,707)		(1,961)		—		5,662		—
Income (loss) before income taxes	1,913		1,422		1,994		1,919		(5,669)		1,579
Income tax provision	(2)		(40)		—		(298)		—		(340)
Net income (loss)	1,915		1,462		1,994		2,217		(5,669)		1,919
Net income attributable to noncontrolling interests	—		—		—		(4)		—		(4)
Net income (loss) attributable to Medtronic	1,915		1,462		1,994		2,213		(5,669)		1,915
Other comprehensive income (loss), net of tax	65		58		65		18		(141)		65
Comprehensive income attributable to noncontrolling interests	—		—		—		(4)		—		(4)
Total comprehensive income (loss)	$	1,980	$	1,520	$	2,059	$	2,231	$	(5,810)	$	1,980

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Nine Months Ended January 24, 2020

Medtronic Senior Notes and Medtronic Luxco Senior Notes


(in millions)	Medtronic plc		Medtronic, Inc.		Medtronic Luxco		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Net sales	$	—	$	1,155	$	—	$	22,916	$	(1,155)	$	22,916

Costs and expenses:
Cost of products sold	—		1,013		—		6,999		(852)		7,160
Research and development expense	—		500		—		1,263		—		1,763
Selling, general, and administrative expense	9		1,241		1		6,499		—		7,750
Amortization of intangible assets	—		12		—		1,305		—		1,317
Restructuring charges, net	—		13		—		74		—		87
Certain litigation charges	—		5		—		271		—		276

Other operating expense (income), net	39		(1,637)		(7)		1,977		(284)		88
Operating profit (loss)	(48)		8		6		4,528		(19)		4,475
Other non-operating (income) expense, net	—		(184)		(660)		(1,245)		1,784		(305)
Interest expense	350		1,372		424		568		(1,784)		930
Equity in net (income) loss of subsidiaries	(4,535)		(2,899)		(4,293)		—		11,727		—
Income (loss) before income taxes	4,137		1,719		4,535		5,205		(11,746)		3,850
Income tax provision	(6)		(199)		—		(112)		—		(317)
Net income (loss)	4,143		1,918		4,535		5,317		(11,746)		4,167
Net income attributable to noncontrolling interests	—		—		—		(24)		—		(24)
Net income (loss) attributable to Medtronic	4,143		1,918		4,535		5,293		(11,746)		4,143
Other comprehensive income (loss), net of tax	165		29		165		(65)		(129)		165
Comprehensive income attributable to noncontrolling interests	—		—		—		(24)		—		(24)
Total comprehensive income (loss)	$	4,308	$	1,947	$	4,700	$	5,228	$	(11,875)	$	4,308

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Three Months Ended January 25, 2019

Medtronic Senior Notes and Medtronic Luxco Senior Notes


(in millions)	Medtronic plc		Medtronic, Inc.		Medtronic Luxco		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Net sales	$	—	$	281	$	—	$	7,546	$	(281)	$	7,546

Costs and expenses:
Cost of products sold	—		223		—		2,206		(164)		2,265
Research and development expense	—		152		—		409		—		561
Selling, general, and administrative expense	2		362		—		2,232		—		2,596
Amortization of intangible assets	—		2		—		434		—		436
Restructuring charges, net	—		3		—		23		—		26
Certain litigation charges	—		12		—		51		—		63
Other operating expense (income), net	15		(827)		—		987		(118)		57
Operating profit (loss)	(17)		354		—		1,204		1		1,542
Other non-operating (income) expense, net	—		(151)		(200)		(480)		760		(71)
Interest expense	125		501		133		244		(760)		243
Equity in net (income) loss of subsidiaries	(1,410)		(678)		(1,343)		—		3,431		—
Income (loss) before income taxes	1,268		682		1,410		1,440		(3,430)		1,370
Income tax provision	(1)		40		—		60		—		99
Net income (loss)	1,269		642		1,410		1,380		(3,430)		1,271
Net income attributable to noncontrolling interests	—		—		—		(2)		—		(2)
Net income (loss) attributable to Medtronic	1,269		642		1,410		1,378		(3,430)		1,269
Other comprehensive income (loss), net of tax	154		45		154		132		(331)		154
Comprehensive income attributable to noncontrolling interests	—		—		—		(2)		—		(2)
Total comprehensive income (loss)	$	1,423	$	687	$	1,564	$	1,510	$	(3,761)	$	1,423

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Nine Months Ended January 25, 2019

Medtronic Senior Notes and Medtronic Luxco Senior Notes


(in millions)	Medtronic plc		Medtronic, Inc.		Medtronic Luxco		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Net sales	$	—	$	1,007	$	—	$	22,411	$	(1,007)	$	22,411

Costs and expenses:
Cost of products sold	—		776		—		6,538		(642)		6,672
Research and development expense	—		496		—		1,240		—		1,736
Selling, general, and administrative expense	8		1,142		—		6,648		—		7,798
Amortization of intangible assets	—		6		—		1,321		—		1,327
Restructuring charges, net	—		14		—		98		—		112
Certain litigation charges	—		90		—		76		—		166
Other operating expense (income), net	40		(1,759)		—		2,336		(339)		278
Operating profit (loss)	(48)		242		—		4,154		(26)		4,322
Other non-operating (income) expense, net	—		(445)		(539)		(1,411)		2,086		(309)
Interest expense	333		1,444		349		686		(2,086)		726
Equity in net (income) loss of subsidiaries	(3,835)		(2,176)		(3,645)		—		9,656		—
Income (loss) before income taxes	3,454		1,419		3,835		4,879		(9,682)		3,905
Income tax provision	(5)		(79)		—		521		—		437
Net income (loss)	3,459		1,498		3,835		4,358		(9,682)		3,468
Net income attributable to noncontrolling interests	—		—		—		(9)		—		(9)
Net income (loss) attributable to Medtronic	3,459		1,498		3,835		4,349		(9,682)		3,459
Other comprehensive income (loss), net of tax	(719)		(965)		(719)		(779)		2,460		(722)
Comprehensive income attributable to noncontrolling interests	—		—		—		(6)		—		(6)
Total comprehensive income (loss)	$	2,740	$	533	$	3,116	$	3,573	$	(7,222)	$	2,740

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Balance Sheet

January 24, 2020

Medtronic Senior Notes and Medtronic Luxco Senior Notes


(in millions)	Medtronic plc		Medtronic, Inc.		Medtronic Luxco		Subsidiary Non-guarantors		Consolidating Adjustments		Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	—	$	185	$	3,524	$	—	$	3,709
Investments	—		—		—		7,919		—		7,919
Accounts receivable, net	—		—		—		6,248		—		6,248
Inventories, net	—		211		—		4,159		(248)		4,122
Intercompany receivable	42		8,807		5		34,982		(43,836)		—

Other current assets	10		195		2		1,838		—		2,045

Total current assets	52		9,213		192		58,670		(44,084)		24,043
Property, plant, and equipment, net	—		1,536		—		3,228		—		4,764
Goodwill	—		2,009		—		38,082		—		40,091
Other intangible assets, net	—		197		—		19,259		—		19,456
Tax assets	—		508		—		1,764		—		2,272
Investment in subsidiaries	58,753		75,008		77,989		—		(211,750)		—
Intercompany loans receivable	—		22		18,296		21,072		(39,390)		—
Other assets	—		377		—		1,819		—		2,196

Total assets	$	58,805	$	88,870	$	96,477	$	143,894	$	(295,224)	$	92,822
LIABILITIES AND EQUITY
Current liabilities:
Current debt obligations	$	—	$	500	$	—	$	344	$	—	$	844
Accounts payable	—		507		—		1,438		—		1,945
Intercompany payable	—		21,383		13,599		8,854		(43,836)		—
Accrued compensation	20		785		—		1,104		—		1,909
Accrued income taxes	—		—		—		457		—		457

Other accrued expenses	25		287		98		3,170		—		3,580

Total current liabilities	45		23,462		13,697		15,367		(43,836)		8,735
Long-term debt	—		9,786		13,522		1,424		—		24,732
Accrued compensation and retirement benefits	—		1,025		—		573		—		1,598
Accrued income taxes	10		760		—		1,968		—		2,738
Intercompany loans payable	6,942		9,012		9,729		13,707		(39,390)		—
Deferred tax liabilities	—		—		—		1,282		—		1,282
Other liabilities	—		262		—		1,522		—		1,784

Total liabilities	6,997		44,307		36,948		35,843		(83,226)		40,869
Shareholders’ equity	51,808		44,563		59,529		107,906		(211,998)		51,808
Noncontrolling interests	—		—		—		145		—		145
Total equity	51,808		44,563		59,529		108,051		(211,998)		51,953
Total liabilities and equity	$	58,805	$	88,870	$	96,477	$	143,894	$	(295,224)	$	92,822

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Balance Sheet

April 26, 2019

Medtronic Senior Notes and Medtronic Luxco Senior Notes


(in millions)	Medtronic plc		Medtronic, Inc.		Medtronic Luxco		Subsidiary Non-guarantors		Consolidating Adjustments		Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	18	$	1	$	4,374	$	—	$	4,393
Investments	—		—		—		5,455		—		5,455
Accounts receivable, net	—		—		—		6,222		—		6,222
Inventories, net	—		188		—		3,792		(227)		3,753
Intercompany receivable	40		9,407		6		19,170		(28,623)		—
Other current assets	10		190		3		1,941		—		2,144
Total current assets	50		9,803		10		40,954		(28,850)		21,967
Property, plant, and equipment, net	—		1,480		—		3,195		—		4,675
Goodwill	—		2,009		—		37,950		—		39,959
Other intangible assets, net	—		99		—		20,461		—		20,560
Tax assets	—		568		—		951		—		1,519
Investment in subsidiaries	64,352		71,123		65,012		—		(200,487)		—
Intercompany loans receivable	3,000		21		27,858		35,398		(66,277)		—
Other assets	—		216		—		798		—		1,014
Total assets	$	67,402	$	85,319	$	92,880	$	139,707	$	(295,614)	$	89,694
LIABILITIES AND EQUITY
Current liabilities:
Current debt obligations	$	—	$	500	$	—	$	338	$	—	$	838
Accounts payable	—		481		—		1,472		—		1,953
Intercompany payable	—		11,971		7,200		9,452		(28,623)		—
Accrued compensation	3		913		—		1,273		—		2,189
Accrued income taxes	—		—		—		567		—		567
Other accrued expenses	20		331		53		2,521		—		2,925
Total current liabilities	23		14,196		7,253		15,623		(28,623)		8,472
Long-term debt	—		14,418		8,621		1,447		—		24,486
Accrued compensation and retirement benefits	—		1,069		—		582		—		1,651
Accrued income taxes	10		692		—		2,136		—		2,838
Intercompany loans payable	17,278		12,613		19,682		16,704		(66,277)		—
Deferred tax liabilities	—		—		—		1,278		—		1,278
Other liabilities	—		133		—		624		—		757
Total liabilities	17,311		43,121		35,556		38,394		(94,900)		39,482
Shareholders' equity	50,091		42,198		57,324		101,192		(200,714)		50,091
Noncontrolling interests	—		—		—		121		—		121
Total equity	50,091		42,198		57,324		101,313		(200,714)		50,212
Total liabilities and equity	$	67,402	$	85,319	$	92,880	$	139,707	$	(295,614)	$	89,694

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Statement of Cash Flows

Nine Months Ended January 24, 2020

Medtronic Senior Notes and Medtronic Luxco Senior Notes


(in millions)	Medtronic plc		Medtronic, Inc.		Medtronic Luxco		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Operating Activities:
Net cash provided by (used in) operating activities	$	130	$	(1,315)	$	365	$	6,604	$	—	$	5,784
Investing Activities:
Acquisitions, net of cash acquired	—		2		—		(201)		—		(199)

Additions to property, plant, and equipment	—		(236)		—		(641)		—		(877)
Purchases of investments	—		—		—		(8,249)		—		(8,249)
Sales and maturities of investments	—		12		—		5,779		—		5,791




Capital contribution paid	—		—		(9,000)		(800)		9,800		—
Return of capital	10,000		—		(3,000)		(7,000)		—		—
Other investing activities	—		(56)		(5)		27		—		(34)
Net cash provided by (used in) investing activities	10,000		(278)		(12,005)		(11,085)		9,800		(3,568)
Financing Activities:

Change in current debt obligations, net	—		—		—		17		—		17


Issuance of long-term debt	—		—		5,567		1		—		5,568
Payments on long-term debt	—		(5,016)		(515)		(75)		—		(5,606)
Dividends to shareholders	(2,170)		—		—		—		—		(2,170)
Issuance of ordinary shares	585		—		—		—		—		585
Repurchase of ordinary shares	(1,208)		—		—		—		—		(1,208)
Net intercompany loan borrowings (repayments)	(7,337)		6,591		6,010		(5,264)		—		—

Capital contribution received	—		—		800		9,000		(9,800)		—
Other financing activities	—		—		(38)		(36)		—		(74)
Net cash provided by (used in) financing activities	(10,130)		1,575		11,824		3,643		(9,800)		(2,888)
Effect of exchange rate changes on cash and cash equivalents	—		—		—		(12)		—		(12)
Net change in cash and cash equivalents	—		(18)		184		(850)		—		(684)
Cash and cash equivalents at beginning of period	—		18		1		4,374		—		4,393
Cash and cash equivalents at end of period	$	—	$	—	$	185	$	3,524	$	—	$	3,709

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Statement of Cash Flows

Nine Months Ended January 25, 2019

Medtronic Senior Notes and Medtronic Luxco Senior Notes


(in millions)	Medtronic plc		Medtronic, Inc.		Medtronic Luxco		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Operating Activities:
Net cash provided by (used in) operating activities	$	100	$	(619)	$	200	$	5,239	$	—	$	4,920
Investing Activities:
Acquisitions, net of cash acquired	—		—		—		(1,615)		—		(1,615)

Additions to property, plant, and equipment	—		(207)		—		(592)		—		(799)
Purchases of investments	—		—		—		(1,987)		—		(1,987)
Sales and maturities of investments	—		76		—		4,083		—		4,159
Capital contribution paid	(18)		(47)		—		—		65		—
Other investing activities	—		—		—		(3)		—		(3)
Net cash provided by (used in) investing activities	(18)		(178)		—		(114)		65		(245)
Financing Activities:

Change in current debt obligations, net	—		—		(696)		—		—		(696)


Issuance of long-term debt	—		—		—		3		—		3
Payments on long-term debt	—		—		—		(29)		—		(29)
Dividends to shareholders	(2,022)		—		—		—		—		(2,022)
Issuance of ordinary shares	891		—		—		—		—		891
Repurchase of ordinary shares	(2,728)		—		—		—		—		(2,728)
Net intercompany loan borrowings (repayments)	3,777		793		814		(5,384)		—		—

Capital contribution received	—		—		—		65		(65)		—
Other financing activities	—		—		17		(7)		—		10
Net cash provided by (used in) financing activities	(82)		793		135		(5,352)		(65)		(4,571)
Effect of exchange rate changes on cash and cash equivalents	—		—		—		(70)		—		(70)
Net change in cash and cash equivalents	—		(4)		335		(297)		—		34
Cash and cash equivalents at beginning of period	—		20		1		3,648		—		3,669
Cash and cash equivalents at end of period	$	—	$	16	$	336	$	3,351	$	—	$	3,703

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Three Months Ended January 24, 2020

CIFSA Senior Notes


(in millions)	Medtronic plc		CIFSA		CIFSA Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Net sales	$	—	$	—	$	—	$	7,717	$	—	$	7,717

Costs and expenses:
Cost of products sold	—		—		—		2,400		—		2,400
Research and development expense	—		—		—		573		—		573
Selling, general, and administrative expense	3		—		1		2,583		—		2,587
Amortization of intangible assets	—		—		—		436		—		436
Restructuring charges, net	—		—		—		13		—		13

Certain litigation charges	—		—		—		108		—		108



Other operating expense (income), net	12		—		—		(51)		—		(39)
Operating profit (loss)	(15)		—		(1)		1,655		—		1,639
Other non-operating (income) expense, net	—		(27)		(179)		(372)		482		(96)
Interest expense	66		189		141		242		(482)		156
Equity in net (income) loss of subsidiaries	(1,994)		(448)		(1,957)		—		4,399		—
Income (loss) before income taxes	1,913		286		1,994		1,785		(4,399)		1,579
Income tax provision	(2)		—		—		(338)		—		(340)
Net income (loss)	1,915		286		1,994		2,123		(4,399)		1,919
Net income attributable to noncontrolling interests	—		—		—		(4)		—		(4)
Net income (loss) attributable to Medtronic	1,915		286		1,994		2,119		(4,399)		1,915
Other comprehensive income (loss), net of tax	65		(35)		65		30		(60)		65
Comprehensive income attributable to noncontrolling interests	—		—		—		(4)		—		(4)
Total comprehensive income (loss)	$	1,980	$	251	$	2,059	$	2,149	$	(4,459)	$	1,980

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Nine Months Ended January 24, 2020

CIFSA Senior Notes


(in millions)	Medtronic plc		CIFSA		CIFSA Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Net sales	$	—	$	—	$	—	$	22,916	$	—	$	22,916

Costs and expenses:
Cost of products sold	—		—		—		7,160		—		7,160
Research and development expense	—		—		—		1,763		—		1,763
Selling, general, and administrative expense	9		1		2		7,738		—		7,750
Amortization of intangible assets	—		—		—		1,317		—		1,317
Restructuring charges, net	—		—		—		87		—		87
Certain litigation charges	—		—		—		276		—		276

Other operating expense (income), net	39		—		(7)		56		—		88
Operating profit (loss)	(48)		(1)		5		4,519		—		4,475
Other non-operating (income) expense, net	—		(122)		(680)		(1,132)		1,629		(305)
Interest expense	350		601		424		1,184		(1,629)		930
Equity in net (income) loss of subsidiaries	(4,535)		(2,635)		(4,274)		—		11,444		—
Income (loss) before income taxes	4,137		2,155		4,535		4,467		(11,444)		3,850
Income tax provision	(6)		—		—		(311)		—		(317)
Net income (loss)	4,143		2,155		4,535		4,778		(11,444)		4,167
Net income attributable to noncontrolling interests	—		—		—		(24)		—		(24)
Net income (loss) attributable to Medtronic	4,143		2,155		4,535		4,754		(11,444)		4,143
Other comprehensive income (loss), net of tax	165		(46)		165		(23)		(96)		165
Comprehensive income attributable to noncontrolling interests	—		—		—		(24)		—		(24)
Total comprehensive income (loss)	$	4,308	$	2,109	$	4,700	$	4,731	$	(11,540)	$	4,308

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Three Months Ended January 25, 2019

CIFSA Senior Notes


(in millions)	Medtronic plc		CIFSA		CIFSA Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Net sales	$	—	$	—	$	—	$	7,546	$	—	$	7,546

Costs and expenses:
Cost of products sold	—		—		—		2,265		—		2,265
Research and development expense	—		—		—		561		—		561
Selling, general, and administrative expense	2		—		1		2,593		—		2,596
Amortization of intangible assets	—		—		—		436		—		436
Restructuring charges, net	—		—		—		26		—		26
Certain litigation charges	—		—		—		63		—		63
Other operating expense, net	15		—		—		42		—		57
Operating profit (loss)	(17)		—		(1)		1,560		—		1,542

Other non-operating (income) expense, net	—		(9)		(207)		(190)		335		(71)
Interest expense	125		23		132		298		(335)		243
Equity in net (income) loss of subsidiaries	(1,410)		(656)		(1,336)		—		3,402		—
Income (loss) before income taxes	1,268		642		1,410		1,452		(3,402)		1,370
Income tax provision	(1)		—		—		100		—		99
Net income (loss)	1,269		642		1,410		1,352		(3,402)		1,271
Net income attributable to noncontrolling interests	—		—		—		(2)		—		(2)
Net income (loss) attributable to Medtronic	1,269		642		1,410		1,350		(3,402)		1,269
Other comprehensive income (loss), net of tax	154		104		154		154		(412)		154
Comprehensive income attributable to noncontrolling interests	—		—		—		(2)		—		(2)
Total comprehensive income (loss)	$	1,423	$	746	$	1,564	$	1,504	$	(3,814)	$	1,423

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Nine Months Ended January 25, 2019

CIFSA Senior Notes


(in millions)	Medtronic plc		CIFSA		CIFSA Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Net sales	$	—	$	—	$	—	$	22,411	$	—	$	22,411

Costs and expenses:
Cost of products sold	—		—		—		6,672		—		6,672
Research and development expense	—		—		—		1,736		—		1,736
Selling, general, and administrative expense	8		1		2		7,787		—		7,798
Amortization of intangible assets	—		—		—		1,327		—		1,327
Restructuring charges, net	—		—		—		112		—		112
Certain litigation charges	—		—		—		166		—		166
Other operating expense, net	40		—		—		238		—		278
Operating profit (loss)	(48)		(1)		(2)		4,373		—		4,322
Other non-operating (income) expense, net	—		(29)		(559)		(614)		893		(309)
Interest expense	333		66		348		872		(893)		726
Equity in net (income) loss of subsidiaries	(3,835)		(2,277)		(3,626)		—		9,738		—
Income (loss) before income taxes	3,454		2,239		3,835		4,115		(9,738)		3,905
Income tax provision	(5)		—		—		442		—		437
Net income (loss)	3,459		2,239		3,835		3,673		(9,738)		3,468
Net income attributable to noncontrolling interests	—		—		—		(9)		—		(9)
Net income (loss) attributable to Medtronic	3,459		2,239		3,835		3,664		(9,738)		3,459
Other comprehensive income (loss), net of tax	(719)		287		(719)		(722)		1,151		(722)
Comprehensive income attributable to non-controlling interests	—		—		—		(6)		—		(6)
Total comprehensive income (loss)	$	2,740	$	2,526	$	3,116	$	2,945	$	(8,587)	$	2,740

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Balance Sheet

January 24, 2020

CIFSA Senior Notes


(in millions)	Medtronic plc		CIFSA		CIFSA Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments		Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	—	$	185	$	3,524	$	—	$	3,709
Investments	—		—		—		7,919		—		7,919
Accounts receivable, net	—		—		—		6,248		—		6,248
Inventories, net	—		—		—		4,122		—		4,122
Intercompany receivable	42		—		1,333		13,623		(14,998)		—
Other current assets	10		—		3		2,032		—		2,045

Total current assets	52		—		1,521		37,468		(14,998)		24,043
Property, plant, and equipment, net	—		—		—		4,764		—		4,764
Goodwill	—		—		—		40,091		—		40,091
Other intangible assets, net	—		—		—		19,456		—		19,456
Tax assets	—		—		—		2,272		—		2,272
Investment in subsidiaries	58,753		68,723		76,908		—		(204,384)		—
Intercompany loans receivable	—		3,545		18,296		37,018		(58,859)		—
Other assets	—		—		—		2,196		—		2,196

Total assets	$	58,805	$	72,268	$	96,725	$	143,265	$	(278,241)	$	92,822
LIABILITIES AND EQUITY
Current liabilities:
Current debt obligations	$	—	$	—	$	—	$	844	$	—	$	844
Accounts payable	—		—		—		1,945		—		1,945
Intercompany payable	—		1,327		13,599		72		(14,998)		—
Accrued compensation	20		—		—		1,889		—		1,909
Accrued income taxes	—		—		—		457		—		457
Other accrued expenses	25		8		104		3,443		—		3,580

Total current liabilities	45		1,335		13,703		8,650		(14,998)		8,735
Long-term debt	—		1,307		13,522		9,903		—		24,732
Accrued compensation and retirement benefits	—		—		—		1,598		—		1,598
Accrued income taxes	10		—		—		2,728		—		2,738
Intercompany loans payable	6,942		27,048		9,970		14,899		(58,859)		—
Deferred tax liabilities	—		—		—		1,282		—		1,282
Other liabilities	—		—		1		1,783		—		1,784

Total liabilities	6,997		29,690		37,196		40,843		(73,857)		40,869
Shareholders’ equity	51,808		42,578		59,529		102,277		(204,384)		51,808
Noncontrolling interests	—		—		—		145		—		145
Total equity	51,808		42,578		59,529		102,422		(204,384)		51,953
Total liabilities and equity	$	58,805	$	72,268	$	96,725	$	143,265	$	(278,241)	$	92,822

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Balance Sheet

April 26, 2019

CIFSA Senior Notes


(in millions)	Medtronic plc		CIFSA		CIFSA Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments		Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	—	$	1	$	4,392	$	—	$	4,393
Investments	—		—		—		5,455		—		5,455
Accounts receivable, net	—		—		—		6,222		—		6,222
Inventories, net	—		—		—		3,753		—		3,753
Intercompany receivable	40		—		1,374		7,212		(8,626)		—
Other current assets	10		—		3		2,131		—		2,144

Total current assets	50		—		1,378		29,165		(8,626)		21,967
Property, plant, and equipment, net	—		—		—		4,675		—		4,675
Goodwill	—		—		—		39,959		—		39,959
Other intangible assets, net	—		—		—		20,560		—		20,560
Tax assets	—		—		—		1,519		—		1,519
Investment in subsidiaries	64,352		39,563		63,651		—		(167,566)		—
Intercompany loans receivable	3,000		4,119		27,858		29,002		(63,979)		—
Other assets	—		—		—		1,014		—		1,014

Total assets	$	67,402	$	43,682	$	92,887	$	125,894	$	(240,171)	$	89,694
LIABILITIES AND EQUITY
Current liabilities:
Current debt obligations	$	—	$	—	$	—	$	838	$	—	$	838
Accounts payable	—		—		—		1,953		—		1,953
Intercompany payable	—		1,308		7,199		119		(8,626)		—
Accrued compensation	3		—		—		2,186		—		2,189
Accrued income taxes	—		—		—		567		—		567
Other accrued expenses	20		11		60		2,834		—		2,925

Total current liabilities	23		1,319		7,259		8,497		(8,626)		8,472
Long-term debt	—		1,354		8,621		14,511		—		24,486
Accrued compensation and retirement benefits	—		—		—		1,651		—		1,651
Accrued income taxes	10		—		—		2,828		—		2,838
Intercompany loans payable	17,278		9,320		19,682		17,699		(63,979)		—
Deferred tax liabilities	—		—		—		1,278		—		1,278
Other liabilities	—		—		1		756		—		757

Total liabilities	17,311		11,993		35,563		47,220		(72,605)		39,482
Shareholders' equity	50,091		31,689		57,324		78,553		(167,566)		50,091
Noncontrolling interests	—		—		—		121		—		121
Total Equity	50,091		31,689		57,324		78,674		(167,566)		50,212
Total liabilities and equity	$	67,402	$	43,682	$	92,887	$	125,894	$	(240,171)	$	89,694

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Statement of Cash Flows

Nine Months Ended January 24, 2020

CIFSA Senior Notes


(in millions)	Medtronic plc		CIFSA		CIFSA Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Operating Activities:
Net cash provided by (used in) operating activities	$	130	$	(497)	$	441	$	5,710	$	—	$	5,784
Investing Activities:
Acquisitions, net of cash acquired	—		—		—		(199)		—		(199)

Additions to property, plant, and equipment	—		—		—		(877)		—		(877)
Purchases of investments	—		—		—		(8,249)		—		(8,249)
Sales and maturities of investments	—		—		—		5,791		—		5,791

Capital contribution paid	—		(9,348)		(9,301)		(800)		19,449		—
Return of capital	10,000		—		(3,000)		(7,000)		—		—
Other investing activities	—		—		(5)		(29)		—		(34)
Net cash provided by (used in) investing activities	10,000		(9,348)		(12,306)		(11,363)		19,449		(3,568)
Financing Activities:

Change in current debt obligations, net	—		—		—		17		—		17


Issuance of long-term debt	—		—		5,567		1		—		5,568
Payments on long-term debt	—		(44)		(515)		(5,047)		—		(5,606)
Dividends to shareholders	(2,170)		—		—		—		—		(2,170)
Issuance of ordinary shares	585		—		—		—		—		585
Repurchase of ordinary shares	(1,208)		—		—		—		—		(1,208)
Net intercompany loan borrowings (repayments)	(7,337)		588		6,231		518		—		—

Capital contribution received	—		9,301		800		9,348		(19,449)		—
Other financing activities	—		—		(34)		(40)		—		(74)
Net cash provided by (used in) financing activities	(10,130)		9,845		12,049		4,797		(19,449)		(2,888)
Effect of exchange rate changes on cash and cash equivalents	—		—		—		(12)		—		(12)
Net change in cash and cash equivalents	—		—		184		(868)		—		(684)
Cash and cash equivalents at beginning of period	—		—		1		4,392		—		4,393
Cash and cash equivalents at end of period	$	—	$	—	$	185	$	3,524	$	—	$	3,709

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Statement of Cash Flows

Nine Months Ended January 25, 2019

CIFSA Senior Notes


(in millions)	Medtronic plc		CIFSA		CIFSA Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments		Total
Operating Activities:
Net cash provided by (used in) operating activities	$	100	$	(62)	$	219	$	4,663	$	—	$	4,920
Investing Activities:
Acquisitions, net of cash acquired	—		—		—		(1,615)		—		(1,615)

Additions to property, plant, and equipment	—		—		—		(799)		—		(799)
Purchases of investments	—		—		—		(1,987)		—		(1,987)
Sales and maturities of investments	—		—		—		4,159		—		4,159
Capital contributions paid	(18)		(187)		—		—		205		—
Other investing activities	—		—		—		(3)		—		(3)
Net cash provided by (used in) investing activities	(18)		(187)		—		(245)		205		(245)
Financing Activities:

Change in current debt obligations, net	—		—		(696)		—		—		(696)


Issuance of long-term debt	—		—		—		3		—		3
Payments on long-term debt	—		—		—		(29)		—		(29)
Dividends to shareholders	(2,022)		—		—		—		—		(2,022)
Issuance of ordinary shares	891		—		—		—		—		891
Repurchase of ordinary shares	(2,728)		—		—		—		—		(2,728)
Net intercompany loan borrowings (repayments)	3,777		249		795		(4,821)		—		—

Capital contributions received	—		—		—		205		(205)		—
Other financing activities	—		—		17		(7)		—		10
Net cash provided by (used in) financing activities	(82)		249		116		(4,649)		(205)		(4,571)
Effect of exchange rate changes on cash and cash equivalents	—		—		—		(70)		—		(70)
Net change in cash and cash equivalents	—		—		335		(301)		—		34
Cash and cash equivalents at beginning of period	—		—		1		3,668		—		3,669
Cash and cash equivalents at end of period	$	—	$	—	$	336	$	3,367	$	—	$	3,703

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

UNDERSTANDING OUR FINANCIAL INFORMATION

The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company, or we, us, or our). For a full understanding of financial condition and results of operations, you should read this discussion along with Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended April 26, 2019. In addition, you should read this discussion along with our consolidated financial statements and related notes thereto at and for the three and nine months ended January 24, 2020.

Financial Trends

Throughout this Management’s Discussion and Analysis, we present certain financial measures that we use to evaluate the operational performance of the Company and as a basis for strategic planning; however, such financial measures are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, financial measures presented in accordance with U.S. GAAP. We generally use non-GAAP financial measures to facilitate management's review of the operational performance of the Company and as a basis for strategic planning. We believe that non-GAAP financial measures provide information useful to investors in understanding the Company's underlying operational performance and trends and may facilitate comparisons with the performance of other companies in the medical technologies industry.

As presented in the GAAP to Non-GAAP Reconciliations section below, our non-GAAP financial measures exclude the impact of certain charges or benefits that contribute to or reduce earnings and that may affect financial trends, and include certain charges or benefits that result from transactions or events that we believe may or may not recur with similar materiality or impact to our operations in future periods (Non-GAAP Adjustments).

In the event there is a Non-GAAP Adjustment recognized in our operating results, the tax cost or benefit attributable to that item is separately calculated and reported. Because the effective rate can be significantly impacted by the Non-GAAP Adjustments that take place during the period, we often refer to our tax rate using both the effective rate and the non-GAAP nominal tax rate (Non-GAAP Nominal Tax Rate). The Non-GAAP Nominal Tax Rate is calculated as the income tax provision, adjusted for the impact of Non-GAAP Adjustments, as a percentage of income before income taxes, excluding Non-GAAP Adjustments.

Free cash flow is a non-GAAP financial measure calculated by subtracting property, plant, and equipment additions from operating cash flows.

Refer to the “GAAP to Non-GAAP Reconciliations," "Income Taxes," and "Free Cash Flow" sections for reconciliations of the non-GAAP financial measures to their most directly comparable financial measures prepared in accordance with U.S. GAAP.

EXECUTIVE LEVEL OVERVIEW

Medtronic is among the world's largest medical technology, services, and solutions companies - alleviating pain, restoring health, and extending life for millions of people around the world. Our primary products include those for cardiac rhythm disorders, cardiovascular disease, advanced and general surgical care, respiratory and monitoring solutions, renal care, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat, and diabetes conditions.

The table below presents net income attributable to Medtronic and our diluted earnings per share for the three and nine months ended January 24, 2020 and January 25, 2019:


	Three months ended										Nine months ended
(in millions, except per share data)	January 24, 2020		January 25, 2019		% Change		January 24, 2020		January 25, 2019		% Change
Net income attributable to Medtronic	$	1,915	$	1,269	51	%	$	4,143	$	3,459	20	%
Diluted earnings per share	$	1.42	$	0.94	51	%	$	3.07	$	2.54	21	%

The increase in net income attributable to Medtronic and diluted earnings per share (EPS) for the three months ended January 24, 2020, as compared to the corresponding period in the prior fiscal year, was primarily attributable to a $558 million tax benefit related to a valuation allowance release and a decrease in interest expense.

The increase in net income attributable to Medtronic and diluted EPS for the nine months ended January 24, 2020, as compared to the corresponding period in the prior fiscal year, was primarily attributable to a $558 million tax benefit related to a valuation allowance release and the change in other operating (income) expense, net, offset by the increase in interest expense due to the tender and early redemption of senior notes during the period. Refer to the "Costs and Expenses" section of this Management's Discussion and Analysis for more information on the items impacting net income attributable to Medtronic and diluted EPS during the three and nine months ended January 24, 2020.

GAAP to Non-GAAP Reconciliations The tables below present our GAAP to Non-GAAP reconciliations for the three and nine months ended January 24, 2020 and January 25, 2019:


	Three months ended January 24, 2020
(in millions, except per share data)	Income Before Income Taxes		Income Tax Provision		Net Income Attributable to Medtronic		Diluted EPS⁽¹⁾		Effective Tax Rate
GAAP	$	1,579	$	(340)	$	1,915	$	1.42	(21.5)	%
Non-GAAP Adjustments:
Restructuring and associated costs ⁽²⁾	97		16		81		0.06		16.5
Acquisition-related items ⁽³⁾	28		3		25		0.02		10.7
Certain litigation charges	108		1		107		0.08		0.9

Medical device regulations ⁽⁵⁾	13		2		11		0.01		15.4
Amortization of intangible assets	436		68		368		0.27		15.6
Certain tax adjustments, net ⁽⁶⁾	—		558		(558)		(0.41)		—
Non-GAAP	$	2,261	$	308	$	1,949	$	1.44	13.6	%

	Three months ended January 25, 2019
(in millions, except per share data)	Income Before Income Taxes		Income Tax Provision		Net Income Attributable to Medtronic		Diluted EPS⁽¹⁾		Effective Tax Rate
GAAP	$	1,370	$	99	$	1,269	$	0.94	7.2	%
Non-GAAP Adjustments:
Restructuring and associated costs ⁽²⁾	66		12		54		0.04		18.2
Acquisition-related items	17		5		12		0.01		29.4
Certain litigation charges	63		12		51		0.04		19.0
(Gain)/loss on minority investments ⁽⁴⁾	(7)		(1)		(6)		—		14.3
IPR&D charges ⁽⁷⁾	11		3		8		0.01		27.3
Exit of businesses ⁽⁸⁾	69		13		56		0.04		18.8
Amortization of intangible assets	436		65		371		0.27		14.9
Certain tax adjustments, net ⁽⁹⁾	—		64		(64)		(0.05)		—
Non-GAAP	$	2,025	$	272	$	1,751	$	1.29	13.4	%

(1)Amounts in this column have been intentionally rounded to the nearest $0.01 and, therefore, may not sum.

(2)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.

(3)The charges primarily include costs incurred in connection with legacy-Covidien enterprise resource planning deployment activities, business combination related costs, and changes in the fair value of contingent consideration.

(4)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

(5)The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.

(6)The benefit relates to the release of a valuation allowance on certain net operating losses.

(7)The charges were recognized in connection with the impairment of in-process research and development ("IPR&D") assets.

(8)The net charge relates to business exits and is primarily comprised of intangible asset impairments.

(9)The net benefit relates to the impact of U.S. tax reform, intercompany legal entity restructuring, and the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Minimally Invasive Therapies Group on July 29, 2017.


	Nine months ended January 24, 2020
(in millions, except per share data)	Income Before Income Taxes		Income Tax Provision		Net Income Attributable to Medtronic		Diluted EPS⁽¹⁾		Effective Tax Rate
GAAP	$	3,850	$	(317)	$	4,143	$	3.07	(8.2)	%
Non-GAAP Adjustments:
Restructuring and associated costs ⁽²⁾	315		47		268		0.20		14.9
Acquisition-related items ⁽³⁾	74		9		65		0.05		12.2
Certain litigation charges	276		33		243		0.18		12.0
(Gain)/loss on minority investments ⁽⁴⁾	(11)		(2)		(9)		(0.01)		18.2
Debt tender premium and other charges ⁽⁵⁾	406		86		320		0.24		21.2
Medical device regulations ⁽⁶⁾	31		4		27		0.02		12.9
Exit of businesses ⁽⁷⁾	41		6		35		0.03		14.6
Contribution to the Medtronic Foundation	80		18		62		0.05		22.5
Amortization of intangible assets	1,317		203		1,114		0.82		15.4
Certain tax adjustments, net ⁽⁸⁾	—		839		(839)		(0.62)		—
Non-GAAP	$	6,379	$	926	$	5,429	$	4.02	14.5	%

	Nine months ended January 25, 2019
(in millions, except per share data)	Income Before Income Taxes		Income Tax Provision		Net Income Attributable to Medtronic		Diluted EPS⁽¹⁾		Effective Tax Rate
GAAP	$	3,905	$	437	$	3,459	$	2.54	11.2	%
Non-GAAP Adjustments:
Restructuring and associated costs ⁽²⁾	256		40		216		0.16		15.6
Acquisition-related items	57		13		44		0.03		22.8
Certain litigation charges	166		24		142		0.10		14.5
(Gain)/loss on minority investments ⁽⁴⁾	(92)		(9)		(83)		(0.06)		9.8
IPR&D charges ⁽⁹⁾	26		3		23		0.02		11.5
Exit of businesses⁽⁷⁾	149		31		118		0.09		20.8
Amortization of intangible assets	1,327		199		1,128		0.83		15.0
Certain tax adjustments, net ⁽¹⁰⁾	—		35		(35)		(0.03)		—
Non-GAAP	$	5,794	$	773	$	5,012	$	3.69	13.3	%

(1)Amounts in this column have been intentionally rounded to the nearest $0.01 and, therefore, may not sum.

(2)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.

(5)The charges, which include $413 million recognized in interest expense and ($7 million) recognized in other operating (income) expense, net, primarily relate to the early redemption of approximately $5.2 billion of senior notes.

(6)The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.

(7)The net charges relate to the exit of businesses and are primarily comprised of intangible asset impairments.

(8)The net benefit primarily relates to the release of a valuation allowance on certain net operating losses and the impact of tax reform in Switzerland and the United States.

(9)The charges represent acquired IPR&D in connection with an asset acquisition.

(10)The net benefit relates to the impact of U.S. tax reform, intercompany legal entity restructuring, and the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Minimally Invasive Therapies Group on July 29, 2017.

NET SALES

Segment and Division

The table below illustrates net sales by segment and division for the three and nine months ended January 24, 2020 and January 25, 2019:


	Three months ended⁽¹⁾								Nine months ended⁽¹⁾
(in millions)	January 24, 2020		January 25, 2019		% Change		January 24, 2020		January 25, 2019		% Change
Cardiac Rhythm & Heart Failure	$	1,393	$	1,397	—	%	$	4,201	$	4,295	(2)	%
Coronary & Structural Heart	948		913		4		2,844		2,736		4
Aortic, Peripheral, & Venous	478		476		—		1,420		1,424		—
Cardiac and Vascular Group	2,819		2,786		1		8,464		8,455		—
Surgical Innovations	1,474		1,434		3		4,345		4,224		3
Respiratory, Gastrointestinal, & Renal	702		690		2		2,073		1,999		4
Minimally Invasive Therapies Group	2,176		2,124		2		6,418		6,223		3
Brain Therapies	795		732		9		2,307		2,107		10
Spine	674		655		3		2,023		1,963		3
Specialty Therapies	340		325		5		996		956		4
Pain Therapies	303		314		(4)		910		942		(3)
Restorative Therapies Group	2,111		2,026		4		6,235		5,968		5
Diabetes Group	610		610		—		1,798		1,765		2
Total	$	7,717	$	7,546	2	%	$	22,916	$	22,411	2	%

(1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

Our performance displays our continued execution against our three growth strategies: therapy innovation, globalization, and economic value. We continue to allocate our capital to higher growth markets and new opportunities that create competitive advantages and capitalize on the long-term trends in healthcare: namely, the desire to improve clinical outcomes; the growing demand for expanded access to care; and the optimization of cost and efficiency within healthcare systems.

We continue to see an acceleration in our innovation cycle within our therapy innovation growth strategy. Our segments invest in a pipeline of groundbreaking medical technology, with several recent product launches and adoption of new therapies contributing to net sales growth. We remain focused on our globalization strategy, as net sales in emerging markets grew 12 percent and 10 percent during the three and nine months ended January 24, 2020, respectively, as compared to the corresponding periods in the prior fiscal year. Our emerging market performance continues to benefit from geographic diversification, with strong, balanced results in these markets around the world. Finally, in our third growth strategy, economic value, we continue to execute our value-based healthcare signature programs and aggressively develop unique, value-based healthcare solutions that directly link our therapies to improving outcomes and deliver improved economic value to the payers and providers. We remain focused on leading the shift to healthcare payment systems that reward value and improved patient outcomes over volume.

During the first quarter of fiscal year 2020, we realigned our divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines previously included in Specialty Therapies to a product line under Brain Therapies. As a result, the fiscal year 2019 results have been recast to adjust for this realignment.

Segment and Market Geography

The table below includes net sales by market geography for each of our segments for the three and nine months ended January 24, 2020 and January 25, 2019:


	U.S.⁽¹⁾⁽⁴⁾										Non-U.S. Developed Markets⁽²⁾⁽⁴⁾								Emerging Markets⁽³⁾⁽⁴⁾
	Three months ended										Three months ended								Three months ended
(in millions)	January 24, 2020		January 25, 2019		% Change		January 24, 2020		January 25, 2019		% Change		January 24, 2020		January 25, 2019		% Change
Cardiac and Vascular Group	$	1,366	$	1,369	—	%	$	915	$	924	(1)	%	$	538	$	493	9	%
Minimally Invasive Therapies Group	934		930		—		791		796		(1)		451		398		13
Restorative Therapies Group	1,409		1,354		4		436		435		—		266		237		12
Diabetes Group	312		348		(10)		236		213		11		63		49		29
Total	$	4,021	$	4,001	—	%	$	2,377	$	2,368	—	%	$	1,318	$	1,177	12	%

	U.S.⁽¹⁾⁽⁴⁾										Non-U.S. Developed Markets⁽²⁾⁽⁴⁾								Emerging Markets⁽³⁾⁽⁴⁾
	Nine months ended										Nine months ended								Nine months ended
(in millions)	January 24, 2020		January 25, 2019		% Change		January 24, 2020		January 25, 2019		% Change		January 24, 2020		January 25, 2019		% Change
Cardiac and Vascular Group	$	4,182	$	4,240	(1)	%	$	2,735	$	2,766	(1)	%	$	1,547	$	1,449	7	%
Minimally Invasive Therapies Group	2,769		2,659		4		2,364		2,396		(1)		1,285		1,168		10
Restorative Therapies Group	4,187		4,005		5		1,278		1,275		—		770		688		12
Diabetes Group	930		1,006		(8)		693		619		12		176		140		26
Total	$	12,068	$	11,910	1	%	$	7,069	$	7,056	—	%	$	3,778	$	3,445	10	%

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(4)Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

Net sales in the U.S. for the three months ended January 24, 2020 remained flat, which was attributable to growth in our Restorative Therapies Group, partially offset by declines in our Diabetes Group. Net sales increases in the U.S. for the nine months ended January 24, 2020 were primarily attributable to growth in our Restorative Therapies and Minimally Invasive Therapies Groups, offset by declines in our Diabetes and Cardiac and Vascular Groups. Currency had an unfavorable effect on net sales in non-U.S. developed markets and emerging markets for the three and nine months ended January 24, 2020 of $46 million and $289 million, respectively. Net sales remained nearly flat in non-U.S. developed markets for the three and nine months ended January 24, 2020, attributable to sales declines in Western Europe, offset by net sales growth in Japan. Net sales growth in emerging markets continues to reflect our broad diversification as we experienced strong performance across the market geography in each of our segments.

Regarding the Covid-19 outbreak (COVID-19), our top concern is the health and well-being of our employees in China and across the globe. We have activated response teams in China, the Asia Pacific region, and globally, and we remain vigilant in monitoring COVID-19. As the Chinese healthcare system is focused on containing the spread of the virus, hospitals in China have experienced a slowing of medical device procedure rates, and, consequently, we are seeing procedure delays. We expect COVID-19 to have a negative impact on our fourth quarter financial results, but given the fluidity of the situation, the duration and magnitude of the impact are difficult to assess or predict at this time. China comprises approximately seven percent of the Company’s revenue. We purchase many of the components, raw materials, and services needed to globally manufacture our products from numerous suppliers in various countries, including China. Although we work closely with our suppliers to try to ensure continuity of supply while maintaining high quality and reliability, the supply of these components, raw materials, and services may be interrupted or insufficient, in certain instances, as a direct result of the COVID-19 outbreak.

Looking ahead, our segments are likely to face competitive product launches and pricing pressure, geographic macro-economic risks, reimbursement challenges, impacts from changes in the mix of our product offerings and timing of product registration

approvals, replacement cycle challenges, and fluctuations in currency exchange rates. Additionally, changes in procedural volumes could affect our Cardiac and Vascular, Minimally Invasive Therapies, and Restorative Therapies Groups.

Cardiac and Vascular Group

The Cardiac and Vascular Group’s products include pacemakers, insertable and external cardiac monitors, cardiac resynchronization therapy devices (CRT-D), implantable cardioverter defibrillators (ICD), leads and delivery systems, ventricular assist systems, ablation products, electrophysiology catheters, products for the treatment of atrial fibrillation, information systems for the management of patients with Cardiac Rhythm & Heart Failure devices, products designed to reduce surgical site infections, coronary and peripheral stents and related delivery systems, balloons and related delivery systems, endovascular stent graft systems, heart valve replacement technologies, cardiac tissue ablation systems, and open heart and coronary bypass grafting surgical products. The Cardiac and Vascular Group also includes Care Management Services and Cath Lab Managed Services (CLMS) within the Cardiac Rhythm & Heart Failure division. The Cardiac and Vascular Group’s net sales for the three months ended January 24, 2020 were $2.8 billion, which represents growth of 1 percent compared to the three months ended January 25, 2019. Net sales for the nine months ended January 24, 2020 were $8.5 billion, which were flat compared to the nine months ended January 25, 2019. Currency had an unfavorable impact on net sales for the three and nine months ended January 24, 2020 of $18 million and $116 million, respectively. The Cardiac and Vascular Group's net sales for the three and nine months ended January 24, 2020, as compared to the corresponding periods in the prior fiscal year, were primarily driven by growth in Coronary & Structural Heart offset by decreases in Cardiac Rhythm & Heart Failure.

Cardiac Rhythm & Heart Failure net sales for the three and nine months ended January 24, 2020 were $1.4 billion and $4.2 billion, respectively, which was flat compared to the three months ended January 25, 2019 and a decline of 2 percent compared to the nine months ended January 25, 2019. Cardiac Rhythm & Heart Failure net sales for the three and nine months ended January 24, 2020 were driven by declines in ICDs and CRT-Ds due to replacement cycles and LVAD headwinds as a result of competitive pressures in the U.S. These declines were partially offset by growth in Pacing, AF Solutions, and the Reveal LINQ insertable cardiac monitoring system. The growth in Pacing was due to the continued strong adoption of the Micra transcatheter pacing system. The growth in AF Solutions was driven by Arctic Front cryoblation products.

Coronary & Structural Heart net sales for the three and nine months ended January 24, 2020 were $948 million and $2.8 billion, respectively, an increase of 4 percent as compared to the corresponding periods in the prior fiscal year. Coronary & Structural Heart net sales growth for the three and nine months ended January 24, 2020 was driven by transcathether aortic valves, reflecting expansion into the low risk patient population, as well as growth of our guide catheters. This growth was partially offset by declines in drug-eluting stents.

Aortic, Peripheral, & Venous net sales for the three and nine months ended January 24, 2020 were $478 million and $1.4 billion, respectively, which was flat when compared to the corresponding periods in the prior fiscal year, with growth in Aortic and Venous offsetting declines in Peripheral. Aortic net sales growth for the three and nine months ended January 24, 2020 was driven by the continued momentum from the launch of the Valiant Navion thoracic stent graft system. Venous net sales growth for the three and nine months ended January 24, 2020 was driven by the ongoing adoption of the VenaSeal vein closure system. Peripheral net sales decline for the three and nine months ended January 24, 2020 was due to drug-coated balloons, as uncertainty around Paclitaxel continues to impact the market.

Looking ahead, we expect our Cardiac and Vascular Group could be affected by the following:

•Continued acceptance and growth from penetration of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform into intermediate risk indication globally.

•Acceptance and growth of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform for the treatment of patients determined to be at low risk with surgery.

•Changes to the U.S. Medicare national coverage determination for transcatheter aortic valve replacement that will allow approximately 30 percent more U.S. centers to offer the therapy to patients.

•Continued expansion and training of field support to increase coverage in the U.S. centers performing transcatheter aortic valve replacement procedures.

•Continued acceptance and growth from Evolut PRO, which provides industry-leading hemodynamics, reliable delivery, and advanced sealing with an excellent safety profile, as well as acceptance of our next generation Evout Pro Plus TAVR valve which launched late in the prior quarter.

•Continued acceptance and growth of the CRT-P quadripolar pacing system.

•Continued acceptance and growth of the Claria MRI CRT-D system with EffectivCRT Diagnostic and Effective CRT during AF algorithm.

•Acceptance and growth of the Cobalt and Crome portfolio of ICDs and CRT-Ds, both of which received CE Mark approval after the end of the third quarter.

•Continued growth of our Micra transcatheter pacing system. Micra AV received U.S. FDA approval the last week of the third quarter, which expands the Micra target population from 15 percent to 55 percent of pacemaker patients.

•Continued acceptance and growth from the Azure XT and S SureScan pacing systems. Azure pacemakers feature Medtronic-exclusive BlueSync technology, which enables automatic, secure wireless remote monitoring with increased device longevity.

•Changes in the U.S. heart transplant guidelines as well as a competitor's product launch as it relates to our LVAD business.

•Continued growth, adoption, and utilization of the TYRX Envelope for implantable devices driven by the favorable results of the WRAP-IT clinical study.

•Continued acceptance of Care Management Services as post-acute care services becoming even more critical in bundled payment models for different interventions or therapies.

•Continued acceptance and growth from the VenaSeal vein closure system in the U.S., for which reimbursement payment was established in January 2018 and payer coverage has been gradually increasing. The VenaSeal system is a unique non-thermal solution to address superficial venous disease that provides improved patient comfort, reduces the recovery time, and eliminates the risk of thermal nerve injury.

•Continued acceptance and growth from the Valiant family of thoracic stent grafts, including the Valiant Navion.

•Ongoing impact of Paclitaxel safety concerns affecting our drug-coated balloons.

Minimally Invasive Therapies Group

The Minimally Invasive Therapies Group’s products span the entire continuum of patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications. The products include those for advanced and general surgical products including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, advanced ablation, interventional lung, ventilators, capnography, airway products, sensors, dialysis, and monitors. The Minimally Invasive Therapies Group’s net sales for the three and nine months ended January 24, 2020 were $2.2 billion and $6.4 billion, respectively, an increase of 2 percent and 3 percent, respectively, as compared to the corresponding periods in the prior fiscal year. Currency had an unfavorable impact on net sales for the three and nine months ended January 24, 2020 of $15 million and $95 million, respectively. Also impacting sales growth was the upgrade of the Group's enterprise resource planning (ERP) system in the U.S. and Canada, resulting in a temporary slowdown in the ability to supply customers, which in some cases resulted in lost procedures for the three months ended January 24, 2020.

Surgical Innovations net sales for the three and nine months ended January 24, 2020 were $1.5 billion and $4.3 billion, respectively, increases of 3 percent as compared to the corresponding periods in the prior fiscal year. Surgical Innovations net sales growth was driven primarily by strong sales in Advanced Energy, led by the LigaSure Exact Dissector and L-Hook Laparoscopic Sealer/Divider, Sonicision curved jaw cordless ultrasonic dissection system, and Valleylab FT10 energy platform. Also driving growth for fiscal year 2020 was growth in Advanced Stapling, led by the Endo GIA and EEA circular stapler platforms with Tri-Staple technology, and growth in Wound Closure led by the V-Loc wound closure device and Lung Health with ILLUMISITE and LUNGGPS patient management platforms.

Respiratory, Gastrointestinal, & Renal net sales for the three and nine months ended January 24, 2020 were $702 million and $2.1 billion, respectively, an increase of 2 percent and 4 percent, respectively, as compared to the corresponding periods in the prior fiscal year. Respiratory, Gastrointestinal, & Renal net sales growth was driven by strength in Patient Monitoring, including the Nellcor pulse oximetry, BIS brain monitoring consumables, and INVOS cerebral oximetry sensor consumables, along with growth in GI & Hepatology, including PillCam capsule endoscopy systems, Bravo calibration-free reflux testing

systems, and EndoFLIP imaging systems. Also driving growth for fiscal year 2020 was growth in Respiratory Interventions, including the continued adoption of ventilators and video laryngoscopy products.

Looking ahead, we expect our Minimally Invasive Therapies Group could be affected by the following:

•Continued acceptance and future growth of Open-to-MIS techniques and tools supported by our efforts to transition open surgery to MIS (minimally invasive surgery). The Open-to-MIS initiative focuses on furthering our presence in and working to optimize open surgery globally, while capturing the market opportunity that exists in transitioning open procedures to MIS, whether through traditional MIS, or advanced technologies including robotics.

•Continued acceptance and future growth of powered stapling and energy platform, along with our ability to execute ongoing strategies to develop, gain regulatory approval, and commercialize new products including our surgical soft tissue robotics platform.

•The July 29, 2017 divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. We have entered into Transition Manufacturing Agreements (TMAs) with Cardinal Health, Inc. (Cardinal). The TMAs will contribute to net sales and are designed to ensure and facilitate an orderly transfer of business operations for a transition period of two to five years, with the ability to extend upon mutual agreement of the parties.

•Our ability to execute ongoing strategies in order to address the competitive pressure of reprocessing of our vessel sealing disposables and growth of surgical soft tissue robotics procedures in the U.S.

•Our ability to create markets and drive product and procedures into emerging markets. We have high quality and cost-effective surgical products designed for customers in emerging markets such as the ValleyLab LS10 single channel vessel sealing generator, which is compatible with our line of LigaSure instruments and designed for simplified use and affordability.

•Continued acceptance and growth within the end stage renal disease market. The population of patients treated for end stage renal disease globally is expected to double over the next decade. We plan to grow our therapy innovation with scalable and affordable dialysis delivery while investing in vascular creation and maintenance technologies. In addition, the HD multi-pass system reduces infrastructure by requiring less water, less start-up costs, and offers high quality ultrapure dialysate treatment. We are expecting regulatory filing in first half of calendar year 2021, with launch following regulatory clearance in targeted countries.

•Continued elevation of the standard of care for respiratory compromise, a progressive condition impacting a patient’s ability to breathe effectively which leverages our market leading MicroStream capnography technology.

•Continued acceptance and growth in patient monitoring, airway, and ventilation management. Key products in this area include the Puritan Bennett 980 ventilator, Microstream Capnography, Nellcor pulse oximetry system with OxiMax technology, Shiley tracheostomy and endotracheal tubes, and McGRATH MAC video laryngoscopes.

•Continued and future acceptance of less invasive standards of care in Gastrointestinal and Hepatology products, including the areas of GI Diagnostic and Therapeutic product lines. Recently launched products include the PillCam COLON capsule endoscopy, the Barrx platform through ablation with the Barrx 360 Express catheter, EndoFLIP imaging systems, Bravo Calibration-free reflux testing, and the Emprint ablation system with Thermosphere Technology, which maintains predictable spherical ablation zones throughout procedures reducing procedure time and cost.

•Continued and future acceptance of Interventional Lung Solutions. Products include the superDimension GenCut core biopsy system and the Triple Needle Cytology Brush, a lung tissue biopsy tool for use with the superDimension navigation system. The superDimension system enables a minimally invasive approach to accessing difficult-to-reach areas of the lung, which may aid in the diagnosis of lung cancer.

•Expanding the use of less invasive treatments and furthering our commitment to improving options for women with abnormal uterine bleeding. Our expanded and strengthened surgical offerings are expected to complement our global gynecology business.

Restorative Therapies Group

The Restorative Therapies Group's products focus on various areas of the spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies and drug delivery systems for the treatment of chronic pain, movement disorders, epilepsy, overactive bladder, urinary retention, fecal incontinence and gastroparesis, as well as products to treat conditions of the ear, nose, and throat (ENT), and systems that incorporate advanced energy surgical instruments. The Restorative Therapies Group also manufactures and sells image-guided surgery and intra-operative imaging systems, robotic guidance systems used in robot assisted spine procedures, and therapies to treat diseases of the vasculature in and around the brain, including coils, neurovascular stents and flow diversion products. The Restorative Therapies Group’s net sales for the three and nine months ended January 24, 2020 were $2.1 billion and $6.2 billion, respectively, an increase of 4 percent and 5 percent, respectively, as compared to the corresponding periods in the prior fiscal year. Currency had an unfavorable impact on net sales for the three and nine months ended January 24, 2020 of $8 million and $50 million, respectively. Net sales growth for the three and nine months ended January 24, 2020 was driven by the Brain Therapies, Spine, and Specialty Therapies divisions. Net sales growth for the three and nine months ended January 24, 2020 was partially offset by modest declines in Pain Therapies.

Brain Therapies net sales for the three and nine months ended January 24, 2020 were $795 million and $2.3 billion, an increase of 9 percent and 10 percent, respectively, as compared to the corresponding periods in the prior fiscal year. Brain Therapies net sales growth was driven by strong growth in both Neurovascular and Neurosurgery. Neurovascular net sales growth was driven by continued strength in both the Hemorrhagic and Ischemic stroke businesses. The Hemorrhagic stroke business saw growth in flow diversion products, particularly with our Pipeline Flex flow diversion system. The Ischemic stroke business saw continued strong adoption of the recently launched Solitaire X stent retriever products as well as our Riptide aspiration system and React catheters. Neurosurgery net sales growth was driven by continued strong demand for the StealthStation S8 surgical navigation systems, O-Arm Imaging Systems, and Mazor X Stealth robotic guidance systems, as well as strong uptake of the Midas Rex MR8 high-speed drill system fully launched in the U.S. during the second quarter of fiscal year 2020.

Spine net sales for the three and nine months ended January 24, 2020 were $674 million and $2.0 billion, respectively, an increase of 3 percent as compared to the corresponding periods in the prior fiscal year. Net sales growth for the three and nine months ended January 24, 2020 was driven by continued success of our Surgical Synergy strategy, which integrates our spinal implants with enabling technologies such as imaging, navigation, power instruments, nerve monitoring and Mazor robotics sold by our Neurosurgery business. These enabling technologies also contributed to the strong performance in Neurosurgery within our Brain Therapies division. Core Spine also contributed to sales growth through new product penetration from recently launched products, including the Infinity OCT System, T2 Stratosphere, and Prestige LP cervical disc system. Also contributing to growth in Core Spine was the acquisition of Titan Spine in the first quarter of fiscal year 2020. For the three months ended January 24, 2020, growth was partially offset by declines in bone morphogenetic protein (BMP).

Specialty Therapies net sales for the three and nine months ended January 24, 2020 were $340 million and $996 million, respectively, an increase of 5 percent and 4 percent, respectively, as compared to the corresponding periods in the prior fiscal year. Net sales growth was driven by capital equipment sales of the StealthStation ENT surgical navigation system, intraoperative NIM nerve monitoring system, and powered ENT instruments in ENT. For the three months ended January 24, 2020, growth in ENT was partially offset by modest declines in Pelvic Health.

Pain Therapies net sales for the three and nine months ended January 24, 2020 were $303 million and $910 million, respectively, a decrease of 4 percent and 3 percent, respectively, as compared to the corresponding periods in the prior fiscal year. For the three and nine months ended January 24, 2020, the decrease in net sales was driven by the continued overall slowdown in the U.S. spinal cord stimulation market, partially offset by growth in emerging markets.

Looking ahead, we expect our Restorative Therapies Group could be affected by the following:

•Continued acceptance and growth of the Solitare FR revascularization device for treatment of acute ischemic stroke and the Pipeline Embolization Devices, endovascular treatments for large or giant wide-necked brain aneurysms.

•Continued acceptance of our React Catheter and Riptide aspiration system, along with our next-generation Solitaire revascularization device.

•Continued growth from Neurosurgery StealthStation and O-Arm Imaging Systems, Midas, and ENT Navigation and Power Systems.

•Continued sales of Mazor robotic units and associated market adoption of robot-assisted spine procedures, including the Mazor X Stealth, our integrated robotics and navigation platform, which received U.S. FDA approval in November 2018.

•Strengthening of our position as a global leader in enabling technologies for spine surgery as a result of the December 2018 acquisition of Mazor Robotics.

•Strengthening of our position in the spine titanium interbody implant marketplace as a result of the June 2019 acquisition of Titan Spine.

•Continued adoption of our integrated solutions through the Surgical Synergy strategy, which integrates our spinal implants with enabling technologies such as imaging, navigation, power instruments, nerve monitoring, and Mazor robotics.

•Market acceptance and continued global adoption of innovative new Spine products and procedural solutions, such as our Infinity OCT System and Prestige LP cervical disc system.

•Growth in the broader vertebral compression fracture (VCF) and adjacent markets, as we continue to pursue the development of other therapies to treat more patients with VCF, including continued success of both the Kyphon V vertebroplasty system and the Osteocool RF Spinal Tumor ablation system.

•Market acceptance and continued global adoption of our Intellis spinal cord stimulator, DTM (differential target multiplexed) proprietary waveform, Evolve workflow algorithm, and Snapshot reporting to treat chronic pain in major markets around the world.

•Acceptance and future growth of our Percept PC deep brain stimulation (DBS) device with Brainsense technology.

•Ongoing obligations under the U.S. FDA consent decree entered in April 2015 relating to the SynchroMed drug infusion system and the Neuromodulation quality system. The U.S. FDA lifted its distribution requirements on our implantable drug pump in October 2017 and its warning letter in November 2017.

•Continued acceptance of our devices for the treatment of Parkinson's Disease, epilepsy and other movement disorders.

•Continued acceptance and growth of our Specialty Therapies, including our InterStim therapy with InterStim II and InterStim Micro neurostimulators for the treatment of the symptoms of overactive bladder, urinary retention, and bowel incontinence, and capital equipment sales of the Stealth Station ENT surgical navigation system and intraoperative NIM nerve monitoring system.

Diabetes Group

The Diabetes Group's products include insulin pumps, continuous glucose monitoring (CGM) systems, and insulin pump consumables. The Diabetes Group’s net sales for the three and nine months ended January 24, 2020 were $610 million and $1.8 billion, respectively, which was flat and an increase of 2 percent, respectively, as compared to the corresponding periods in the prior fiscal year. Currency had an unfavorable impact on net sales for the three and nine months ended January 24, 2020 of $5 million and $28 million, respectively. For the nine months ended January 24, 2020, the Diabetes Group's net sales growth was primarily attributable to growth in international markets resulting from sustained strong consumer demand for the MiniMed 670G. For the three months ended January 24, 2020, international growth was offset by declines in our U.S. business as a result of increased competition, while for the nine months ended January 24, 2020 these US. declines only partially offset international growth. Global sales of integrated CGM sensors contributed to sales for both the three and nine months ended January 24, 2020, driven by sensor attachment rates associated with the global adoption of sensor-augmented insulin pump systems. We also launched our Next Tech Pathway program during the three months ended January 24, 2020 to ensure eligible patients have access to upcoming product innovations.

Looking ahead, we expect our Diabetes Group could be affected by the following:

•Increasing pump competition in an expanding U.S. market.

•Continued patient demand for the MiniMed 670G system, the first hybrid closed loop system in the world. The system is powered by SmartGuard technology, which mimics some of the functions of a healthy pancreas by providing two levels of automated insulin delivery, maximizing Time in Range with reduced user input. Approximately 237,000 trained, active users are benefiting from SmartGuard technology.

•Continued acceptance and future growth internationally for the MiniMed 670G system. This system received CE mark in June 2018 and is now commercialized in Canada, Australia, Chile and in select European and Central American countries. The global adoption of sensor-augmented insulin pump systems has resulted in

strong sensor attachment rates. Reimbursement in Germany was received in September 2019 and we expect additional launches outside the U.S. in the fourth quarter of fiscal year 2020.

•Changes in medical reimbursement policies and programs, along with additional payor coverage of the MiniMed 670G system.

•Our ability to execute ongoing strategies to develop, gain regulatory approval, commercialize, and gain customer acceptance of new products, including our MiniMed 780G advanced hybrid closed loop system, as well as our Personalized Closed Loop system that was granted "Breakthrough Device" designation by the U.S. FDA. These technologies feature our next-generation algorithms designed to improve Time in Range by further automating insulin delivery.

•Continued acceptance and growth of the Guardian Connect CGM system which displays glucose information directly to a smartphone.

•Continued partnership with UnitedHealthcare as the preferred in-network provider of insulin pumps, giving their members, including pediatric patients 7 years and above, access to our advanced diabetes technology and comprehensive support services.

CRITICAL ACCOUNTING ESTIMATES

We have used various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 26, 2019.

The preparation of the consolidated financial statements, in conformity with U.S. GAAP, requires us to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates reflect our best judgment about economic and market conditions and the potential effects on the valuation and/or carrying value of assets and liabilities based upon relevant information available. We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

Our critical accounting estimates include the following:

Litigation Contingencies We are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. The outcomes of these legal actions are not completely within our control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures or result in lost revenues or limit our ability to conduct business in the applicable jurisdictions. Estimating probable losses from our litigation and governmental proceedings is inherently difficult, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery; involve unsubstantiated or indeterminate claims for damages; potentially involve penalties, fines, or punitive damages; or could result in a change in business practice. Our significant legal proceedings are discussed in Note 17 to the current period's consolidated financial statements.

Income Tax Reserves We establish reserves when, despite our belief that our tax return positions are fully supportable, we believe that certain positions are likely to be challenged and that we may or may not prevail. Under U.S. GAAP, if we determine that a tax position is more likely than not of being sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50 percent likely of being realized upon settlement. We presume that all tax positions will be examined by a taxing authority with full knowledge of all relevant information. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions across our global operations. We regularly monitor our tax positions and tax liabilities. We reevaluate the technical merits of our tax positions and recognize an uncertain tax benefit, or derecognize a previously recorded tax benefit, when there is (i) a completion of a tax audit, (ii) effective settlement of an issue, (iii) a change in applicable tax law including a tax case or legislative guidance, or (iv) the expiration of the applicable statute of limitations. Significant judgment is required in accounting for tax reserves. Although we believe that we have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, consolidated earnings, financial position and/or cash flows.

Valuation of Intangible Assets and Goodwill When we acquire a business, the assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. Goodwill is the excess of the purchase price over the estimated

fair value of net assets of acquired businesses. Intangible assets primarily include patents, trademarks, tradenames, customer relationships, purchased technology, and IPR&D. Determining the fair value of intangible assets acquired as part of a business combination requires us to make significant estimates. These estimates include the amount and timing of projected future cash flows of each project or technology, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks.

The test for goodwill impairment requires us to make several estimates to determine fair value, most of which are based on projected future cash flows. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value. We assess the impairment of goodwill at the reporting unit level annually as of the first day of the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired.

We test definite-lived intangible assets for impairment when an event occurs or circumstances change that would indicate the carrying amount of the assets or asset group may be impaired. Our tests are based on future cash flows that require significant judgment with respect to future revenue and expense growth rates, appropriate discount rates, asset groupings, and other assumptions and estimates. We use estimates that are consistent with our business plans and a market participant's view of the assets being evaluated. Actual results may differ from our estimates due to a number of factors including, among others, changes in competitive conditions, timing of regulatory approval, results of clinical trials, changes in worldwide economic conditions, and fluctuations in currency exchange rates.

We assess the impairment of indefinite-lived intangible assets annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Our impairment tests of indefinite-lived intangible assets require us to make several estimates to determine fair value, including projected future cash flows and discount rates.

NEW ACCOUNTING PRONOUNCEMENTS

Information regarding new accounting pronouncements is included in Note 2 to the current period's consolidated financial statements.

ACQUISITIONS

Information regarding acquisitions is included in Note 4 to the current period's consolidated financial statements.

COSTS AND EXPENSES

The following is a summary of cost of products sold, research and development, and selling, general, and administrative expenses as a percent of net sales:


	Three months ended						Nine months ended
	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cost of products sold	31.1	%	30.0	%	31.2	%	29.8	%
Research and development expense	7.4	%	7.4	%	7.7	%	7.7	%
Selling, general, and administrative expense	33.5	%	34.4	%	33.8	%	34.8	%

Cost of Products Sold We continue to focus on reducing our costs of production through supplier management, manufacturing improvements, and optimizing our manufacturing network.

Cost of products sold for the three and nine months ended January 24, 2020 was $2.4 billion and $7.2 billion, respectively. The increase in cost of products sold as a percentage of net sales for the three and nine months ended January 24, 2020, as compared to the corresponding periods in the prior fiscal year, was driven by increased restructuring and associated costs and increased duty, driven in part by increased China tariffs on inbound products. Additionally, for the nine months ended January 24, 2020, we incurred increased expenses to overcome the sterilization shortage in our Minimally Invasive Therapies Group. Cost of products sold for the three and nine months ended January 24, 2020 included $50 million and $117 million, respectively, of restructuring and associated costs, as compared to $21 million and $58 million, respectively, for the corresponding periods in the prior fiscal year.

Research and Development Expense We remain committed to accelerating the development of meaningful innovations to deliver better patient outcomes at appropriate costs that lead to enhanced quality of life and may be validated by clinical and economic evidence. We are also focused on expanding access to quality healthcare. Research and development expense for the three and nine months ended January 24, 2020 was $573 million and $1.8 billion, respectively.

Selling, General, and Administrative Expense Our goal is to continue to leverage selling, general, and administrative expense initiatives and to continue to realize cost synergies expected from our acquisitions. Selling, general, and administrative expense primarily consists of salaries and wages, other administrative costs, such as professional fees and marketing expenses, and certain acquisition and restructuring expenses.

Selling, general, and administrative expense for the three and nine months ended January 24, 2020 was $2.6 billion and $7.8 billion, respectively. The decrease in selling, general, and administrative expense as a percentage of net sales for the three and nine months ended January 24, 2020 benefited from our Enterprise Excellence program, cost containment efforts, and continued net sales growth. Selling, general, and administrative expense for the three and nine months ended January 25, 2019 also included expenses incurred to fulfill our Transition Service Agreements (TSAs) that we entered into with Cardinal in conjunction with the July 29, 2017 divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses.

The following is a summary of other costs and expenses:


	Three months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Amortization of intangible assets	$	436	$	436	$	1,317	$	1,327
Restructuring charges, net	13		26		87		112
Certain litigation charges	108		63		276		166

Other operating (income) expense, net	(39)		57		88		278
Other non-operating income, net	(96)		(71)		(305)		(309)
Interest expense	156		243		930		726

Amortization of Intangible Assets Amortization of intangible assets includes the amortization expense of our definite-lived intangible assets, consisting of purchased patents, trademarks, tradenames, customer relationships, purchased technology, and other intangible assets. Amortization expense was $436 million and $1.3 billion for the three and nine months ended January 24, 2020, and January 25, 2019, respectively.

Restructuring Charges, Net

In the third quarter of fiscal year 2018, we announced a multi-year global Enterprise Excellence Program designed to drive long-term business growth and sustainable efficiency. The Enterprise Excellence Program is expected to further leverage our global size and scale as well as enhance the customer and employee experience.

The Enterprise Excellence Program is focused on three objectives:

•Global Operations - integrating and enhancing global manufacturing and supply processes, systems and site presence to improve quality, delivery cost and cash flow

•Functional Optimization - enhancing and leveraging global operating models and systems across several enabling functions to improve productivity and employee experience

•Commercial Optimization - optimizing certain processes, systems and models to improve productivity and the customer experience

The Enterprise Excellence Program is designed to drive operating margin improvement as well as fund investment in strategic growth initiatives, with expected annual gross savings of more than $3.0 billion from cost reductions and leverage of our fixed infrastructure by the end of fiscal year 2022. Approximately $500 million to $700 million of gross annual savings are expected to be achieved each fiscal year through the end of fiscal year 2022.

The Enterprise Excellence Program is expected to result in pre-tax restructuring charges of approximately $1.6 billion to $1.8 billion, the vast majority of which are expected to be incurred by the end of fiscal year 2022 and result in cash outlays to be substantially complete by the end of fiscal year 2023. Approximately half of the estimated charges are related to employee termination benefits. The remaining charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. We expect these costs to be recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income.

For the three and nine months ended January 24, 2020, we recognized charges of $97 million and $328 million, respectively. Additionally, we incurred accrual adjustments of $13 million for the nine months ended January 24, 2020, related to certain employees identified for termination finding other positions within Medtronic. For the three and nine months ended January 24, 2020, charges included $13 million and $94 million, respectively, recognized within restructuring charges, net in the consolidated statements of income, primarily comprised of employee termination benefits. For the three and nine months ended January 24, 2020, charges also included costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses, including $50 million and $111 million, respectively, recognized within cost of products sold and $34 million and $111 million, respectively, recognized within selling, general, and administrative expense in the consolidated statements of income. For the nine months ended January 24, 2020, cost of products sold also included $6 million of fixed asset write-downs.

For the three and nine months ended January 25, 2019, we recognized charges of $69 million and $264 million, respectively. For the three and nine months ended January 25, 2019, charges included $29 million and $120 million, respectively, recognized within restructuring charges, net in the consolidated statements of income, primarily comprised of employee termination benefits. For the three and nine months ended January 25, 2019, charges also included costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses, including $21 million and $58 million, respectively, recognized within cost of products sold and $19 million and $73 million, respectively, recognized within selling, general and administrative expense in consolidated statements of income. For the nine months ended January 25, 2019, selling, general and administrative expense also included $13 million of fixed asset write-downs.

For additional information about our restructuring programs, refer to Note 5 to the current period's consolidated financial statements.

Certain Litigation Charges We classify litigation charges and gains related to significant legal matters as certain litigation charges. During the three and nine months ended January 24, 2020 we recognized $108 million and $276 million, respectively, of certain litigation charges related to probable and estimable damages for significant legal matters. During the three and nine months ended January 25, 2019, we recognized $63 million and $166 million of certain litigation charges, respectively.

Other Operating (Income) Expense, Net Other operating (income) expense, net primarily includes royalty income and expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in the fair value of contingent consideration, TSA income, a commitment to the Medtronic Foundation, and charges associated with business exits. For the three and nine months ended January 24, 2020, other operating (income) expense, net was ($39) million and $88 million, respectively, as compared to $57 million and $278 million for the three and nine months ended January 25, 2019, respectively.

For the three months ended January 24, 2020 the change in other operating (income) expense, net was driven by our remeasurement and hedging programs, which, combined, resulted in an $82 million gain, compared to a $36 million gain for the three months ended January 25, 2019. Additionally, for three months ended January 25, 2019, other operating (income) expense, net includes $69 million charge related to business exits. There were no charges related to business exits during the three months ended January 24, 2020. These items were partially offset by changes in the fair value of contingent consideration, which resulted in a $59 million gain for the three months ended January 25, 2019, compared to a $2 million loss for the three months ended January 24, 2020.

For the nine months ended January 24, 2020, the change in other operating (income) expense, net was driven by our remeasurement and hedging programs, which, combined, resulted in a gain of $203 million, compared to $9 million gain for the nine months ended January 25, 2019. For the nine months ended January 24, 2020, other operating (income) expense, net includes charges associated with the exit of businesses of $41 million, compared to $149 million for the nine months ended January 25, 2019. These items were partially offset by changes in the fair value of contingent consideration, which resulted in a $68 million gain for the nine months ended January 25, 2019, compared to a $4 million loss for the nine months ended January 24, 2020. Additionally, for the nine months ended January 24, 2020, other operating (income) expense, net includes an $80 million charge associated with our commitment to the Medtronic Foundation.

Other Non-Operating Income, Net Other non-operating income, net includes the non-service component of net periodic pension and postretirement benefit cost, investment gains and losses, and interest income. For the three months ended January 24, 2020 other non-operating income, net was $96 million, as compared to $71 million for the three months January 25, 2019. The change in other non-operating income, net is primarily attributable to interest income, which was $77 million for the three months ended January 24, 2020, as compared to $55 million for the three months ended January 25, 2019, due to an increase in investments.

For the nine months ended January 24, 2020, other non-operating income, net was $305 million, as compared to $309 million for the nine months ended January 25, 2019. The change in other non-operating income, net is primarily attributable to minority investment gains, partially offset by interest income. Gains on minority investments were $11 million for the nine months ended January 24, 2020, as compared to $92 million for the nine months ended January 25, 2019. Interest income was $238 million for the nine months ended January 24, 2020, as compared to $202 million for the nine months ended January 25, 2019, due to an increase in investments.

Interest Expense Interest expense includes interest incurred on our outstanding borrowings, amortization of debt issuance costs and debt premiums or discounts, amortization of gains or losses on terminated or de-designated interest rate derivative instruments, and charges recognized in connection with the tender and early redemption of senior notes. For the three and nine months ended January 24, 2020, interest expense was $156 million and $930 million, respectively, as compared to $243 million and $726 million for the three and nine months ended January 25, 2019, respectively. The decrease in interest expense during the three months ended January 24, 2020 was primarily due to a decrease in the weighted-average interest rate of outstanding debt obligations, as compared to the corresponding period in the prior fiscal year, driven by our debt issuance and tender transactions in the fourth quarter of fiscal year 2019 and first quarter of fiscal year 2020. The increase in interest expense during the nine months ended January 24, 2020 was primarily driven by $413 million of charges recognized in connection with the tender and early redemption of $5.2 billion of senior notes, partially offset by a decrease in the weighted-average interest rate of outstanding debt obligations due to the aforementioned debt issuance and tender transactions.

INCOME TAXES


	Three months ended									Nine months ended
(in millions)	January 24, 2020			January 25, 2019			January 24, 2020			January 25, 2019
Income tax provision	$	(340)		$	99		$	(317)		$	437
Income before income taxes	1,579			1,370			3,850			3,905
Effective tax rate	(21.5)		%	7.2		%	(8.2)		%	11.2		%

Non-GAAP income tax provision	$	308		$	272		$	926		$	773
Non-GAAP income before income taxes	2,261			2,025			6,379			5,794
Non-GAAP Nominal Tax Rate	13.6		%	13.4		%	14.5		%	13.3		%

Difference between the effective tax rate and Non-GAAP Nominal Tax Rate	35.1		%	6.2		%	22.7		%	2.1		%

Many of the countries we operate in have statutory tax rates lower than our U.S. statutory rate, thereby resulting in an overall effective tax rate less than the U.S. statutory rate of 21 percent. A significant portion of our earnings are generated from operations in Puerto Rico, Switzerland, and Ireland. The statutory tax rates for these jurisdictions range from 12.5 percent to 45.1 percent. Our earnings in Puerto Rico and Switzerland are subject to certain tax incentive grants which provide for tax rates lower than the country statutory tax rates. Unless our tax incentive grants are extended, they will expire between fiscal years 2020 and 2034. The tax incentive grants scheduled to expire during fiscal year 2020 are not expected to have a material impact on our financial results. Refer to Note 14 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 26, 2019 for additional information.

Our effective tax rate for the three and nine months ended January 24, 2020 was (21.5) percent and (8.2) percent, respectively, as compared to 7.2 percent and 11.2 percent for the three and nine months ended January 25, 2019, respectively. The decrease in the effective tax rate for the three and nine months ended January 24, 2020, as compared to the corresponding periods in the prior fiscal year, was primarily due to the impact of certain tax adjustments described below.

Our Non-GAAP Nominal Tax Rate for the three and nine months ended January 24, 2020 was 13.6 percent and 14.5 percent, respectively, as compared to 13.4 percent and 13.3 percent for the three and nine months ended January 25, 2019, respectively. The change in our Non-GAAP Nominal Tax Rate was primarily due to the finalization of certain tax returns, the impact from

the lapse of federal statute of limitations, excess tax benefits related to stock-based compensation, and the impact of year-over-year changes in operational results by jurisdiction. An increase in our Non-GAAP Nominal Tax Rate of 1 percent would result in an additional income tax provision for the three and nine months ended January 24, 2020 of approximately $23 million and $64 million, respectively.

Certain Tax Adjustments

•A net benefit of $12 million associated with the transition tax liability and the impacts of U.S. Tax Reform on deferred tax assets, liabilities, and valuation allowances.

•A benefit of $32 million related to intercompany legal entity restructuring.

•A net benefit of $20 million associated with the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses.

•A net benefit of $25 million associated with the transition tax liability and the impacts of U.S. Tax Reform on deferred tax assets, liabilities, and valuation allowances

•A benefit of $32 million related to intercompany legal entity restructuring.

•A net benefit of $20 million associated with the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses.

LIQUIDITY AND CAPITAL RESOURCES

Our liquidity and capital structure is evaluated regularly within the context of our annual operating and strategic planning process. We consider the liquidity necessary to fund our operations, which includes working capital needs, investments in research and development, property, plant, and equipment, and other operating costs. We also consider capital allocation alternatives that balance returning value to shareholders through dividends and share repurchases, satisfying maturing debt, and acquiring businesses and technology.

Summary of Cash Flows

The following is a summary of cash provided by (used in) operating, investing, and financing activities, the effect of exchange rate changes on cash and cash equivalents, and the net change in cash and cash equivalents:


	Nine months ended
(in millions)	January 24, 2020		January 25, 2019
Cash provided by (used in):
Operating activities	$	5,784	$	4,920
Investing activities	(3,568)		(245)
Financing activities	(2,888)		(4,571)
Effect of exchange rate changes on cash and cash equivalents	(12)		(70)
Net change in cash and cash equivalents	$	(684)	$	34

Operating Activities The $864 million increase in net cash provided was primarily driven by a decrease in cash paid for income taxes and interest, partially offset by an increase in cash paid for Enterprise Excellence restructuring activities, and an increase in cash paid to employees. The decrease in cash paid for income taxes was primarily due to a tax payment associated with the intercompany sale of intellectual property in the first quarter of fiscal year 2019, a lower transition tax payment made in the second quarter of fiscal year 2020 as compared to the corresponding period in the prior year, as well as the timing of estimated tax payments. Cash paid for interest decreased due to a decrease in interest expense and change in timing of interest payments resulting from the debt tenders and issuances in the first quarter of fiscal year 2020 and the fourth quarter of fiscal year 2019. Refer to the "Restructuring Charges, Net" section of this Management's Discussion and Analysis and Note 5 to the current period's consolidated financial statements for information on the Enterprise Excellence program. Cash paid to employees increased due to higher annual incentive plan payouts compared the corresponding period in the prior fiscal year.

Investing Activities The $3.3 billion increase in net cash used was primarily attributable to a decrease in net proceeds from purchases and sales of investments of $4.6 billion and an increase in cash paid for additions of property, plant, and equipment of $78 million during the nine months ended January 24, 2020, partially offset by a decrease in cash paid for acquisitions of $1.4 billion as compared to the corresponding period in the prior fiscal year.

Financing Activities The $1.7 billion decrease in net cash used was primarily attributable to a decrease in net cash used for share repurchases of $1.5 billion and a net increase in short-term borrowings during the nine months ended January 24, 2020, partially offset by a decrease in the issuance of ordinary shares of $306 million, as compared to the corresponding period in the prior fiscal year. Financing cash flows were also impacted by the issuance of $5.6 billion of Euro-denominated senior notes offset by the tender of $5.2 billion of senior notes for $5.6 billion of total consideration.

Free Cash Flow

Free cash flow, a non-GAAP financial measure, is calculated by subtracting additions to property, plant, and equipment from net cash provided by operating activities. Management uses this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to evaluate our operating results. Free cash flow should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Reconciliations between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow are as follows:


	Nine months ended
(in millions)	January 24, 2020		January 25, 2019




Net cash provided by operating activities	$	5,784	$	4,920
Additions to property, plant, and equipment	(877)		(799)
Free cash flow	$	4,907	$	4,121

Debt and Capital

Our capital structure consists of equity and interest-bearing debt. We use a combination of bank borrowings and commercial paper issuances to fund our short-term financing needs. Current debt, including the current portion of our long-term debt and capital lease obligations, at January 24, 2020 was $844 million as compared to $838 million at April 26, 2019. Long-term debt at January 24, 2020 was $24.7 billion as compared to $24.5 billion at April 26, 2019. We utilize unsecured senior debt obligations to meet our long-term financing needs. From time to time, we may repurchase our outstanding debt obligations in the open market or through privately negotiated transactions.

Total debt at January 24, 2020 was $25.6 billion, as compared to $25.3 billion at April 26, 2019. The increase in total debt was primarily driven by the net impact of the issuance and cash tender offers described below.

In June 2019, we issued six tranches of Euro-denominated senior notes with an aggregate principal of €5.0 billion, with maturities ranging from fiscal year 2021 to fiscal year 2050, resulting in cash proceeds of approximately $5.6 billion, net of discounts and issuance costs. We used the net proceeds of the offering to fund the cash tender offer and early redemption described below. The Euro-denominated debt is designated as a net investment hedge of certain of our European operations.

We completed the cash tender offer of $4.6 billion of senior notes for $5.0 billion of total consideration in July 2019. We recognized a loss on debt extinguishment of $413 million in the first quarter of fiscal year 2020, which primarily included cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss on debt extinguishment also included a $16 million charge for the estimated early redemption premium for $533 million of senior notes which were redeemed in August 2019. The loss on debt extinguishment was recognized in interest expense in the consolidated statements of income.

For additional information on the issuance of these senior notes and the subsequent cash tender offer and redemption, refer to Note 7 to the current period's consolidated financial statements. For additional information on the Euro-denominated debt designated as a net investment hedge, refer Note 8 to the current period's consolidated financial statements.

We maintain a commercial paper program for short-term financing, which allows us to issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate amount outstanding at any time of $3.5 billion. At both January 24, 2020 and April 26, 2019, we had no commercial paper outstanding. The issuance of commercial paper reduces the amount of credit available under our existing line of credit, as explained below.

We also have a $3.5 billion five-year syndicated credit facility (Credit Facility) which expires in December 2024. The Credit Facility provides backup funding for the commercial paper program and may also be used for general corporate purposes. The Credit Facility provides us with the ability to increase our borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. At each anniversary date of the Credit Facility, but not more than twice prior to the maturity date, we could also request a one-year extension of the maturity date. At January 24, 2020 and April 26, 2019, no amounts were outstanding under the Credit Facility.

Interest rates on advances of our Credit Facility are determined by a pricing matrix, based on our long-term debt ratings assigned by Standard & Poor's Ratings Services (S&P) and Moody's Investors Service (Moody’s). For additional information on our credit ratings status by S&P and Moody's, refer to the "Liquidity" section of this Management's Discussion and Analysis. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreements also contain customary covenants, all of which we were in compliance with at January 24, 2020.

We repurchase our ordinary shares from time to time as part of our focus on returning value to our shareholders. In June 2017, our Board of Directors authorized the expenditure of up to $5.0 billion for new share repurchases. In March 2019, our Board of Directors authorized an incremental $6.0 billion for repurchase of our ordinary shares. There is no specific time period associated with these repurchase authorizations. During the three and nine months ended January 24, 2020, we repurchased a total of 2.1 million and 10.6 million shares, respectively, at an average price per share of $114.04 and $105.12, respectively. At January 24, 2020, we had approximately $6.1 billion remaining under the share repurchase program authorized by our Board of Directors.

For more information on credit arrangements, refer to Note 7 to the current period's consolidated financial statements and Note 7 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 26, 2019.

Liquidity

Our liquidity sources at January 24, 2020 include $3.7 billion of cash and cash equivalents and $7.9 billion of current investments. Additionally, we maintain a commercial paper program (no commercial paper outstanding at January 24, 2020) and Credit Facility. See discussion above regarding changes in our cash and cash equivalents and commercial paper program and Credit Facility.

Our investments include available-for-sale debt securities, including U.S. and non-U.S. government and agency securities, corporate debt securities, mortgage-backed securities, other asset-backed securities, and auction rate securities. Some of our investments may experience reduced liquidity due to changes in market conditions and investor demand. For the three and nine months ended January 24, 2020, the total other-than-temporary impairment losses on available-for-sale debt securities were not significant. Based on our assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which we are invested, we believe we have recognized all necessary other-than-temporary impairments as we do not have the intent to sell, nor is it more likely than not that we will be required to sell, before recovery of the amortized cost. At January 24, 2020, we have $26 million of gross unrealized losses on our aggregate available-for-sale debt securities of $8.0 billion. If market conditions deteriorate, some of these holdings may experience other-than-temporary impairment in the future, which could adversely affect our financial results. We are required to use estimates and assumptions in our valuation of investments, which requires a high degree of judgment, and therefore, actual results could differ materially from estimates. Refer to Note 6 to the current period's consolidated financial statements for additional information regarding fair value measurements.

The table below includes our short-term and long-term debt ratings from S&P and Moody's at both January 24, 2020 and April 26, 2019:

Agency Rating⁽¹⁾

January 24, 2020

April 26, 2019

Standard & Poor's Ratings Services

Long-term debt

Short-term debt

A-1

Moody's Investors Service

Long-term debt

Short-term debt

P-2

(1) Agency ratings are subject to change, and there may be no assurance that an agency will continue to provide ratings and/or maintain its current ratings. A security rating is not a recommendation to buy, sell or hold securities, and may be subject to revision or withdrawal at any time by the rating agency, and each rating should be evaluated independently of any other rating.

S&P and Moody's long-term debt ratings and short-term debt ratings at January 24, 2020 were unchanged as compared to the ratings at April 26, 2019. We do not expect the S&P and Moody's ratings to have a significant impact on our liquidity or future flexibility to access additional liquidity given our balance sheet and Credit Facility and related commercial paper program.

We have future contractual obligations and other minimum commercial commitments that are entered into in the normal course of business. We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, and/or cash flows. Refer to the "Off-Balance Sheet Arrangements and Long-Term Contractual Obligations" section of this Management's Discussion and Analysis for more information on these obligations and commitments.

Note 17 to the current period's consolidated financial statements provides information regarding amounts we have accrued related to legal matters. In accordance with U.S. GAAP, we record a liability in our consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. Actual settlements may be different than estimated and could have a material effect on our consolidated earnings, financial position, and/or cash flows.

We record tax liabilities in our consolidated financial statements for amounts that we expect to repatriate from subsidiaries (to the extent the repatriation would be subject to tax); however, no tax liabilities are recorded for amounts that we consider to be permanently reinvested. We removed our permanently reinvested assertion on the undistributed earnings of certain foreign subsidiaries with a U.S. parent which were subject to the transition tax and all earnings of these subsidiaries through April 27, 2018. We have reasserted for certain earnings of such subsidiaries through April 27, 2018 which were not subject to the transition tax. We expect to have access to the majority of our cash flows in the future. In addition, we continue to evaluate our legal entity structure supporting our business operations, and to the extent such evaluation results in a change to our overall business structure, we may be required to accrue for additional tax obligations.

We believe our balance sheet and liquidity provide us with flexibility, and that our cash, cash equivalents, and current investments, as well as our Credit Facility and related commercial paper program, will satisfy our foreseeable operating needs for at least the next 12 months. We regularly review our capital needs and consider various investing and financing alternatives to support our requirements.

Off-Balance Sheet Arrangements and Long-Term Contractual Obligations

There have been no material changes to our long-term contractual obligations as reported in our most recent Annual Report filed on Form 10-K for the fiscal year ended April 26, 2019.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, and other written reports and oral statements made by or with the approval of one of the Company’s executive officers from time to time, may include “forward-looking” statements. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans, objectives of management for future operations and current expectations or forecasts of future results, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Our forward-looking statements may include statements related to our growth and growth strategies, developments in the markets for our products, therapies and services, financial results, product development launches and effectiveness, research and development strategy, regulatory approvals, competitive strengths, restructuring and cost-saving initiatives, intellectual property rights, litigation and tax matters, government investigations, mergers and acquisitions, divestitures, market acceptance of our products, therapies and services, accounting estimates, financing activities, ongoing contractual obligations, working capital adequacy, value of our investments, our effective tax rate, our expected returns to shareholders, and sales efforts. In some cases, such statements may be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “will,” and similar words or expressions. Forward-looking statements in this Quarterly Report include, but are not limited to, statements regarding our ability to drive long-term shareholder value, development and future launches of products and continued or future acceptance of products, therapies and services in our segments; expected timing for completion of research studies relating to our products; market positioning and performance of our products, including stabilization of certain product markets; divestitures and the potential benefits thereof; the costs and benefits of integrating previous acquisitions; anticipated timing for U.S. FDA and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; acquisitions and investment initiatives, as well as integration of acquired companies into our operations; the resolution of tax matters; the effectiveness of our development activities in reducing patient care costs and hospital stay lengths; our approach towards cost containment; our expectations regarding health care costs, including potential changes to reimbursement policies and pricing pressures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and government investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment of dividends and redemption of shares; the continued strength of our balance sheet and liquidity; our accounts receivable exposure; and the potential impact of our compliance with governmental regulations and accounting guidance.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the “Risk Factors” section and elsewhere in our Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. One must carefully consider forward-looking statements and understand that such forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and involve a variety of risks and uncertainties, known and unknown, including, among others, those discussed in the sections entitled “Government Regulation and Other Considerations” within “Item 1. Business” and “Item 1A. Risk Factors” in our Annual Report on Form 10-K, as well as those related to:

•competition in the medical device industry;

•reduction or interruption in our supply;

•laws and government regulations;

•quality problems;

•liquidity shortfalls;

•decreasing prices and pricing pressure;

•fluctuations in currency exchange rates;

•changes in applicable tax rates;

•changes in tax laws and regulations as well as positions taken by taxing authorities;

•adverse regulatory action;

•delays in regulatory approvals;

•litigation results;

•self-insurance;

•commercial insurance;

•health care policy changes;

•international operations;

•cybersecurity incidents;

•failure to complete or achieve the intended benefits of acquisitions or divestitures; or

•disruption of our current plans and operations.

Consequently, no forward-looking statement may be guaranteed and actual results may vary materially from those projected in the forward-looking statements. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements, and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, whether as a result of any new information, future events, or otherwise, we have no current intention of doing so except to the extent required by applicable law.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

CURRENCY EXCHANGE RATE RISK

Due to the global nature of our operations, we are exposed to currency exchange rate changes which may cause fluctuations in earnings and cash flows. We use operational and economic hedges, including currency exchange rate derivative instruments to manage the impact of currency exchange rate fluctuations. In order to minimize earnings and cash flow volatility resulting from currency exchange rate fluctuations, we enter into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated transactions in other currencies and changes in the value of specific assets and liabilities. At inception of the contract, the derivative instrument is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of our derivative instruments are the Euro, Japanese Yen, and British Pound. Fluctuations in the currency exchange rates of currency exposures that are unhedged, such as in certain emerging markets, may result in future earnings and cash flow volatility. We do not enter into currency exchange rate derivative instruments for speculative purposes.

The gross notional amount of all currency exchange rate derivative instruments outstanding at January 24, 2020 and April 26, 2019 was $12.1 billion and $11.1 billion, respectively. At January 24, 2020, these contracts were in a net unrealized gain position of $235 million. A sensitivity analysis of changes in the fair value of all currency exchange rate derivative contracts at January 24, 2020 indicates that, if the U.S. dollar uniformly strengthened/weakened by 10 percent against all currencies, the fair value of these contracts would increase/decrease by approximately $799 million. Any gains and losses on the fair value of derivative contracts would generally be offset by gains and losses on the underlying transactions. These offsetting gains and losses are not reflected in the above analysis.

In the second quarter of fiscal year 2019, we began accounting for our operations in Argentina as highly inflationary, as the prior three-year cumulative inflation rate exceeded 100 percent. The change did not have a material impact on our results for the three or nine months ended January 24, 2020.

INTEREST RATE RISK

We are subject to interest rate risk on our short-term investments and our borrowings. We manage interest rate risk in the aggregate, while focusing on our immediate and intermediate liquidity needs. Our debt portfolio at January 24, 2020 was comprised of debt predominately denominated in U.S. dollars and Euros, of which substantially all is fixed rate debt. We are also exposed to interest rate changes affecting our investments in interest rate sensitive instruments, which include our marketable debt securities.

A sensitivity analysis of the impact on our interest rate-sensitive financial instruments of a hypothetical 10 basis point change in interest rates, compared to interest rates at January 24, 2020, indicates that the fair value of these instruments would correspondingly change by $30 million.

For a discussion of current market conditions and the impact on our financial condition and results of operations, please see the “Liquidity” section of the current period's Management's Discussion and Analysis. For additional discussion of market risk, refer to Notes 6 and 8 to the current period's consolidated financial statements.

Item 4. Controls and Procedures

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) and changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) are effective.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

During the third quarter of fiscal year 2020, the Company deployed an enterprise resource planning (ERP) software program, SAP, to the Minimally Invasive Therapies Group in the U.S. and Canada. The internal controls were updated to reflect these changes. There have been no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

A discussion of the Company’s policies with respect to legal proceedings is included in the management’s discussion and analysis, and our legal proceedings and other loss contingencies are described in Note 17 to the current period's consolidated financial statements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

The following table provides information about the shares repurchased by the Company during the third quarter of fiscal year 2020:


Fiscal Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as a Part of Publicly Announced Program ⁽¹⁾	Maximum Approximate Dollar Value of Shares that may yet be Purchased Under the Program ⁽¹⁾
10/26/2019 - 11/22/2019	547,952	$	108.74	547,952	$	6,238,903,103
11/23/2019 - 12/27/2019	471,599	112.28		471,599	6,185,952,813
12/28/2019 - 1/24/2020	1,049,571	117.60		1,049,571	6,062,523,192
Total	2,069,122	$	114.04	2,069,122	$	6,062,523,192

(1)In June 2017, the Company's Board of Directors authorized the repurchase of $5.0 billion of the Company’s ordinary shares. In March 2019, the Company's Board of Directors authorized an incremental $6.0 billion for repurchase of the Company's ordinary shares. There is no specific time-period associated with these repurchase authorizations.

Item 6. Exhibits

(a)

Exhibits

10.1

Amended and Restated Credit Agreement (amended as of December 12, 2019).

31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.SCH

Inline XBRL Schema Document.

101.CAL

Inline XBRL Calculation Linkbase Document.

101.DEF

Inline XBRL Definition Linkbase Document.

101.LAB

Inline XBRL Label Linkbase Document.

101.PRE

Inline XBRL Presentation Linkbase Document.

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		MEDTRONIC PUBLIC LIMITED COMPANY
		(Registrant)

Date:	February 28, 2020	/s/ Omar Ishrak
		Omar Ishrak
		Chairman and Chief Executive Officer

Date:	February 28, 2020	/s/ Karen L. Parkhill
		Karen L. Parkhill
		Executive Vice President and
		Chief Financial Officer